"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2008/100581 A1,140-891-305-597-230,2008-08-21,2008,US 2008/0001984 W,2008-02-13,US 88967707 P;;US 88968807 P;;US 88969507 P;;US 88969907 P,2007-02-13,ENERGY FINANCIAL RECONCILIATION SYSTEM AND METHOD,"An energy financial reconciliation method, comprising displaying at least two electricity options for selection by a user, each electricity option identifying attributes associated with the electricity used to process hydrogen fuel and determining an amount of funds to be transferred to an electricity provider based on the amount of purchased hydrogen fuel and the selected electricity option.",BAILEY GREG,BAILEY GREG,,https://lens.org/140-891-305-597-230,Patent Application,yes,3,0,2,2,0,G06Q50/06;;G06Q50/06;;G06Q30/0283;;G06Q30/0283;;G06Q30/0601;;G06Q30/0601,B60L11/18,,0,0,,,,PENDING
2,EP,A1,EP 3971382 A1,117-631-795-380-186,2022-03-23,2022,EP 21198170 A,2021-09-22,GB 202014970 A,2020-09-22,ACOUSTIC DOOR,"An acoustic door (2) comprises a first metallic panel (6) forming a first side of the door, a second metallic panel (8) forming a second side of the door, and a thermal break element (14) of glass fibre joining the first panel to the second panel and extending around a periphery of the door, such that there is no direct contact between the first (6) and second (8) metallic panels.
",IAC ACOUSTIC COMPANY UK LTD,SMITH GREG;;BAILEY PAUL,,https://lens.org/117-631-795-380-186,Patent Application,yes,3,0,2,2,0,E06B3/5892;;E06B3/827;;E06B5/20;;E06B5/162;;E06B5/164;;E06B5/167;;E06B3/263;;E06B2003/26394;;E06B3/2735,E06B5/16;;E06B3/263;;E06B3/273;;E06B3/58;;E06B3/82;;E06B5/20,,0,0,,,,DISCONTINUED
3,US,A1,US 2008/0195508 A1,125-175-246-159-79X,2008-08-14,2008,US 3064008 A,2008-02-13,US 3064008 A;;US 88967707 P;;US 88968807 P;;US 88969907 P;;US 88969507 P,2007-02-13,ENERGY FINANCIAL RECONCILIATION SYSTEM AND METHOD,"An energy financial reconciliation method, comprising displaying at least two electricity options for selection by a user, each electricity option identifying attributes associated with the electricity used to process hydrogen fuel and determining an amount of funds to be transferred to an electricity provider based on the amount of purchased hydrogen fuel and the selected electricity option.",BAILEY GREG;;LOCHHEAD JASON,BAILEY GREG;;LOCHHEAD JASON,,https://lens.org/125-175-246-159-79X,Patent Application,yes,5,5,2,2,0,G06Q50/06;;G06Q50/06;;G06Q30/0283;;G06Q30/0283;;G06Q30/0601;;G06Q30/0601,G06Q30/00;;G06Q10/00,705/27;;705/400,0,0,,,,DISCONTINUED
4,WO,A1,WO 2014/128132 A1,199-459-569-431-937,2014-08-28,2014,EP 2014053163 W,2014-02-18,EP 13155991 A,2013-02-20,MONITORING SYSTEM AND METHOD,"A monitoring system for monitoring the operation of a relief system is provided. The relief system is connected to one or more sources configured to deliver fluid into the relief system and the sources each comprise one or more source sensors for measuring one or more parameters associated with a respective source. The monitoring system is configured to access data storage arranged to store a first set of one or more sources that have previously been identified as delivering fluid into the relief system. The monitoring system comprises a data receiver arranged to receive substantially real-time measurement data from the source sensors and a processor. The processor is configured to a) determine a second set of sources currently delivering fluid into the relief system based on the received source sensor measurement data, b) access the data storage whereby to determine whether said second set of sources matches the first set of sources, and c) generate a relief system operation assessment based on the determination. A computer-implemented method for monitoring the operation of a relief system is also provided.",BP EXPLORATION OPERATING;;BAILEY RICHARD S;;HICKEY GREG,BAILEY RICHARD S;;HICKEY GREG,,https://lens.org/199-459-569-431-937,Patent Application,yes,5,11,1,1,0,F23N5/022;;F23N5/187;;F23N5/242;;F23G7/085;;F23N2223/08,F23N5/02;;F23G7/08;;F23N5/18;;F23N5/24,,0,0,,,,PENDING
5,US,B1,US 11447108 B1,092-951-202-300-169,2022-09-20,2022,US 201815932947 A,2018-05-25,US 201815932947 A;;US 201762707394 P,2017-10-30,Braking control system and method to sysnchronize the operation of the braking of a towed vehicle,A braking control system and method to synchronize the operation of the braking system of a towed vehicle with the braking system of a towing vehicle to match the deceleration and acceleration of the towed vehicle with the deceleration and acceleration of the towing vehicle wherein the braking control system includes a braking device comprising an electrically driven linear actuator coupled between an electric motor and the brake pedal of the towed vehicle and a control device coupled to the electric motor and including logic to control operation of the electrically driven linear actuator to selectively extend and retract the electrically driven linear actuator to selectively depress and release the brake pedal of the towed vehicle as the towing vehicle decelerates and accelerates.,BAILEY DAVID;;CREED RUSSELL;;BAJ GREG;;CREED MONARCH INC,BAILEY DAVID;;CREED RUSSELL;;BAJ GREG,CREED-MONARCH INC (2018-05-05),https://lens.org/092-951-202-300-169,Granted Patent,yes,114,3,1,1,0,B60T8/1708;;B60T8/171;;B60T17/223;;B60T7/20;;B60T13/745;;B60T8/1701;;B60T8/172;;B60T8/3205;;B60T8/321;;B60Y2200/147;;B60T13/72;;B60T13/74;;B60R16/033;;B60T13/46,B60T8/17;;B60R16/033;;B60T8/172;;B60T8/32;;B60T13/46;;B60T13/72;;B60T13/74,,1,0,,,"Arthur W. Fisher III, A prototype of The Creed-Monarch Patriot Model 2012 Auxiliary Braking System including a housing formed by two shells was completed at least as early as Mar. 2011 (Attachment 1). Each shell includes a groove forming a cable channel to receive a cable therein extending between a cavity and a cable connector location to couple a force measuring device to a controller (Composite Attachment 2). A production model of the Patriot Model II Auxiliary Braking System including the cavity and cable channel formed in the two shells (Attachment 3) was first sold to Blue Ox on or about Apr. 25, 2012. (Attachment 4).",ACTIVE
6,US,B2,US 11319504 B2,188-360-055-193-08X,2022-05-03,2022,US 202117146396 A,2021-01-11,US 202117146396 A;;US 202063039862 P,2020-06-16,Lubricant with nanoparticulate additive,An engine oil additive includes carbon nanotubes and boron nitride particulates dispersed within a fluid. The additive is configured to be mixed with a quantity of oil such that the quantity of oil has a concentration from 0.05 to 0.5 grams of carbon nanotubes and of boron nitride particulates per quart of oil to improve the lubricity of the oil. The additive improves the horsepower and torque of the engine while reducing fuel consumption. The carbon nanotubes have an —OH functionalized exterior surface. The carbon nanotubes have a diameter from 1 nanometer to 50 nanometers and have a length from 1 micron to 1000 microns. The boron nitride particulates are hex-boron nitride structures having an average size from 30 nanometers to 500 nanometers.,NOVUM NANO LLC;;SOUTH DAKOTA BOARD OF REGENTS,BAILEY CRAIG;;CHRISTENSEN GREG;;HONG HAIPING,SOUTH DAKOTA BOARD OF REGENTS (2020-10-28);;NOVUM NANO LLC (2020-06-16),https://lens.org/188-360-055-193-08X,Granted Patent,yes,8,0,4,4,0,C10M2201/061;;C10M2201/041;;C10N2040/25;;C10N2070/02;;C10N2030/54;;C10N2030/06;;C10M141/12;;C10M171/06;;B82Y30/00;;C10M169/04;;C10M125/02;;C10M125/26;;C10M2203/003;;C10M2201/041;;B82Y40/00;;C10M2201/14;;C10N2040/25;;C10N2020/06;;C10N2070/02;;B82Y30/00;;C10M2201/082,C10M125/00;;B82Y30/00;;B82Y40/00;;C10M125/02;;C10M125/26;;C10M169/04;;C10N20/06;;C10N40/25;;C10N70/00,,1,0,,,"International Search Report and Written Opinion for PCT/US2021/033125, dated Sep. 9, 2021, 10 pages.",ACTIVE
7,US,A1,US 2022/0251468 A1,064-752-003-480-008,2022-08-11,2022,US 202217713053 A,2022-04-04,US 202217713053 A;;US 202117146396 A;;US 202063039862 P,2020-06-16,LUBRICANT WITH NANOPARTICULATE ADDITIVE,An engine oil additive includes carbon nanotubes and boron nitride particulates dispersed within a fluid. The additive is configured to be mixed with a quantity of oil such that the quantity of oil has a concentration from 0.05 to 0.5 grams of carbon nanotubes and of boron nitride particulates per quart of oil to improve the lubricity of the oil. The additive improves the horsepower and torque of the engine while reducing fuel consumption. The carbon nanotubes have an —OH functionalized exterior surface. The carbon nanotubes have a diameter from 1 nanometer to 50 nanometers and have a length from 1 micron to 1000 microns. The boron nitride particulates are hex-boron nitride structures having an average size from 30 nanometers to 500 nanometers.,NOVUM NANO LLC;;SOUTH DAKOTA BOARD OF REGENTS,BAILEY CRAIG;;CHRISTENSEN GREG;;HONG HAIPING,SOUTH DAKOTA BOARD OF REGENTS (2020-10-28);;NOVUM NANO LLC (2022-03-16),https://lens.org/064-752-003-480-008,Patent Application,yes,3,0,4,4,0,C10M2201/061;;C10M2201/041;;C10N2040/25;;C10N2070/02;;C10N2030/54;;C10N2030/06;;C10M141/12;;C10M171/06;;B82Y30/00;;C10M169/04;;C10M125/02;;C10M125/26;;C10M2203/003;;C10M2201/041;;B82Y40/00;;C10M2201/14;;C10N2040/25;;C10N2020/06;;C10N2070/02;;B82Y30/00;;C10M2201/082,C10M169/04;;C10M125/02;;C10M125/26,,0,0,,,,PENDING
8,US,A1,US 2021/0388285 A1,024-470-877-500-528,2021-12-16,2021,US 202117146396 A,2021-01-11,US 202117146396 A;;US 202063039862 P,2020-06-16,LUBRICANT WITH NANOPARTICULATE ADDITIVE,An engine oil additive includes carbon nanotubes and boron nitride particulates dispersed within a fluid. The additive is configured to be mixed with a quantity of oil such that the quantity of oil has a concentration from 0.05 to 0.5 grams of carbon nanotubes and of boron nitride particulates per quart of oil to improve the lubricity of the oil. The additive improves the horsepower and torque of the engine while reducing fuel consumption. The carbon nanotubes have an —OH functionalized exterior surface. The carbon nanotubes have a diameter from 1 nanometer to 50 nanometers and have a length from 1 micron to 1000 microns. The boron nitride particulates are hex-boron nitride structures having an average size from 30 nanometers to 500 nanometers.,NOVUM NANO LLC;;SOUTH DAKOTA BOARD OF REGENTS,BAILEY CRAIG;;CHRISTENSEN GREG;;HONG HAIPING,SOUTH DAKOTA BOARD OF REGENTS (2020-10-28);;NOVUM NANO LLC (2020-06-16),https://lens.org/024-470-877-500-528,Patent Application,yes,0,0,4,4,0,C10M2201/061;;C10M2201/041;;C10N2040/25;;C10N2070/02;;C10N2030/54;;C10N2030/06;;C10M141/12;;C10M171/06;;B82Y30/00;;C10M169/04;;C10M125/02;;C10M125/26;;C10M2203/003;;C10M2201/041;;B82Y40/00;;C10M2201/14;;C10N2040/25;;C10N2020/06;;C10N2070/02;;B82Y30/00;;C10M2201/082,C10M169/04;;C10M125/02;;C10M125/26,,0,0,,,,ACTIVE
9,WO,A1,WO 2021/257231 A1,129-384-507-093-124,2021-12-23,2021,US 2021/0033125 W,2021-05-19,US 202063039862 P;;US 202117146396 A,2020-06-16,LUBRICANT WITH NANOPARTICULATE ADDITIVE,An engine oil additive includes carbon nanotubes and boron nitride particulates dispersed within a fluid. The additive is configured to be mixed with a quantity of oil such that the quantity of oil has a concentration from 0.05 to 0.5 grams of carbon nanotubes and of boron nitride particulates per quart of oil to improve the lubricity of the oil. The additive improves the horsepower and torque of the engine while reducing fuel consumption. The carbon nanotubes have an -OH functionalized exterior surface. The carbon nanotubes have a diameter from 1 nanometer to 50 nanometers and have a length from 1 micron to 1000 microns. The boron nitride particulates are hex-boron nitride structures having an average size from 30 nanometers to 500 nanometers.,NOVUM NANO LLC;;SOUTH DAKOTA BOARD OF REGENTS,BAILEY CRAIG;;CHRISTENSEN GREG;;HONG HAIPING,,https://lens.org/129-384-507-093-124,Patent Application,yes,5,0,4,4,0,C10M2201/061;;C10M2201/041;;C10N2040/25;;C10N2070/02;;C10N2030/54;;C10N2030/06;;C10M141/12;;C10M171/06;;B82Y30/00;;C10M169/04;;C10M125/02;;C10M125/26;;C10M2203/003;;C10M2201/041;;B82Y40/00;;C10M2201/14;;C10N2040/25;;C10N2020/06;;C10N2070/02;;B82Y30/00;;C10M2201/082,C10M125/02;;C10M125/20;;C10M125/26;;C10N20/06;;C10N40/25,,0,0,,,,PENDING
10,US,A1,US 2008/0216864 A1,192-551-891-023-12X,2008-09-11,2008,US 69769507 A,2007-04-06,US 69769507 A;;US 23732705 A;;US 44056106 A,2005-09-27,METHOD AND SYSTEM FOR DISTRIBUTING GAS FOR A BEVEL EDGE ETCHER,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the top edge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrate is also provided.,SEXTON GREG;;BAILEY ANDREW;;SCHOEPP ALAN,SEXTON GREG;;BAILEY ANDREW;;SCHOEPP ALAN,LAM RESEARCH CORPORATION (2007-03-30),https://lens.org/192-551-891-023-12X,Patent Application,yes,10,31,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,B08B6/00;;C25F3/30,134/1.2;;134/200,0,0,,,,ACTIVE
11,US,A,US 5343605 A,014-948-055-361-941,1994-09-06,1994,US 2295493 A,1993-02-25,US 2295493 A;;US 76598691 A,1991-09-26,"Wire marking, cutting and stripping apparatus and method","A system for marking elongated wire and for cutting the wire and stripping insulation therefrom comprising first structure operable to mark the wire; second structure operable to cut the marked wire and to strip insulation from the wire; the wire extending between and movable between the first and second structures, the first and second structure comprising separate stand-alone devices; and control structure, including an external computer, operatively connected with the first and second structures for controlling operation of the first and second structures in time sequence relation to wire movement therebetween, and/or to control wire marking, wire cutting, and insulation stripping length.",EUBANKS ENG CO,NAZERIAN GREG;;BAILEY RONALD;;HOFFA JACK L,EUBANKS ENGINEERING COMPANY (1993-02-23),https://lens.org/014-948-055-361-941,Granted Patent,yes,81,25,4,38,0,H02G1/1256;;H02G1/1256;;Y10T29/49117;;Y10T29/49117;;Y10T29/5193;;Y10T29/5193;;Y10T29/53209;;Y10T29/53209,H02G1/12,29 33M;;29/747;;29/825;;81/9.51,4,0,,,"Standard Logic Catalogue, EWS 6K Electronic Wire Stripper , Feb. 1974.;;Artos Catalog Sheet, Single Blade, Fully Automatic Wire Processing , 1989.;;Komax 33 Catalogue Sheet, 1988.;;French Patent Application No. 2,525,402 dated Apr. 16, 1982.",EXPIRED
12,WO,A1,WO 2008/124350 A1,159-455-368-867-41X,2008-10-16,2008,US 2008/0058790 W,2008-03-28,US 69769507 A,2007-04-06,METHOD AND SYSTEM FOR DISTRIBUTING GAS FOR A BEVEL EDGE ETCHER,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the top edge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrate is also provided.,LAM RES CORP;;SEXTON GREG;;BAILEY ANDREW III;;SCHOEP ALAN,SEXTON GREG;;BAILEY ANDREW III;;SCHOEP ALAN,,https://lens.org/159-455-368-867-41X,Patent Application,yes,4,0,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,H01L21/306,,0,0,,,,PENDING
13,US,A,US 5539967 A,164-610-749-450-528,1996-07-30,1996,US 38475195 A,1995-02-07,US 38475195 A;;US 22581394 A;;US 2295493 A;;US 76598691 A;;US 65955791 A;;US 61105790 A,1990-11-09,Multiple blade set strip apparatus for cable and wire,"The method of processing wire to cut the wire into sections and to strip sheathing from the wire to expose wire ends at opposite ends of the sections, and by operation of wire feed means and cutter means, the steps that include operating the feed means and cutter means to displace the wire endwise along an axis to a first position; sever the wire thereby to form wire forward and rearward sections, the forward section having a rearward end portion; and, the rearward section having a forward end portion, and; stripping sheathing from the forward section rearward portion and from the rearward section forward portion thereby to expose wire ends at the portions; the cutter means including three blade pairs, each pair including two blades located at opposite sides of the axis, both blades of one pair being displaced toward the wire to sever the wire, and both blades of the remaining two pairs being displaced toward the wire sections to strip sheathing from the rearward and forward portions during controlled endwise displacement of the sections. A sheathing slug or slugs may alternatively be relatively displaced along the wire section or sections to protectively overhang an end or ends of wire metal core, the slug or slugs not then be completely stripped from the section or sections.",EUBANKS ENG CO,NAZERIAN GREG;;BAILEY RONALD;;HOFFA JACK L,,https://lens.org/164-610-749-450-528,Granted Patent,yes,98,13,4,38,0,H02G1/1256;;H02G1/1256;;Y10T29/49117;;Y10T29/49117;;Y10T29/5193;;Y10T29/5193;;Y10T29/53209;;Y10T29/53209,H02G1/12,29 33M;;29/825;;81/9.51,4,0,,,"Standard Logic Catalogue, EWS 6K Electronic Wire Stripper , Feb. 1974.;;Artos Catalog Sheet, Single Blade, Fully Automatic Wire Processing , 1989.;;Komax 33 Catalogue Sheet, 1988.;;French Patent Application No. 2,525,402 dated Apr. 16, 1982.",EXPIRED
14,US,A,US 5412856 A,057-674-473-350-246,1995-05-09,1995,US 22581394 A,1994-04-11,US 22581394 A;;US 2295493 A;;US 76598691 A,1991-09-26,"Wire marking, cutting and stripping apparatus and method","A system for marking elongated wire and for cutting the wire and stripping insulation therefrom comprising first structure operable to mark the wire; second structure operable to cut the marked wire and to strip insulation from the wire; the wire extending between and movable between the first and second structures, the first and second structure comprising separate stand-alone devices; and control structure, including external computer means, operatively connected with the first and second structures for controlling operation of the first and second structures in time sequence relation to wire movement therebetween, and/or to control wire marking, wire cutting, and insulating stripping length.",EUBANKS ENG CO,NAZERIAN GREG;;BAILEY RONALD;;HOFFA JACK L,,https://lens.org/057-674-473-350-246,Granted Patent,yes,89,21,4,38,0,H02G1/1256;;H02G1/1256;;Y10T29/49117;;Y10T29/49117;;Y10T29/5193;;Y10T29/5193;;Y10T29/53209;;Y10T29/53209,H02G1/12,29 33M;;29/747;;29/825;;81/9.51,3,0,,,"Standard Logic Catalogue, EWS 6K Electronic Wire Stripper , Feb. 1974.;;Artos Catalog Sheet, Single Blade, Fully Automatic Wire Processing , 1989.;;Komax 33 Catalogue Sheet, 1988.",EXPIRED
15,KR,A,KR 20100014707 A,169-038-444-861-50X,2010-02-10,2010,KR 20097020476 A,2008-03-28,US 69769507 A,2007-04-06,METHOD AND SYSTEM FOR DISTRIBUTING GAS FOR A BEVEL EDGE ETCHER,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the top edge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrate is also provided.,LAM RES CORP,SEXTON GREG;;BAILEY ANDREW III;;SCHOEP ALAN,,https://lens.org/169-038-444-861-50X,Patent Application,no,0,0,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,H01L21/3065,,0,0,,,,ACTIVE
16,CN,A,CN 101675503 A,026-567-823-239-559,2010-03-17,2010,CN 200880011086 A,2008-03-28,US 2008/0058790 W;;US 69769507 A,2007-04-06,Method and system for distributing gas for a bevel edge etcher,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the topedge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrateis also provided.,LAM RES CORP,GREG SEXTON;;ANDREW BAILEY III;;ALAN SCHOEP,,https://lens.org/026-567-823-239-559,Patent Application,no,0,1,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,H01L21/306,,0,0,,,,DISCONTINUED
17,US,A1,US 2001/0000354 A1,092-861-182-497-312,2001-04-19,2001,US 73382700 A,2000-12-11,US 73382700 A;;US 51057600 A;;US 2295493 A;;US 76598691 A,1991-09-26,"Wire marking, cutting and stripping apparatus and method","
   A system for marking elongated wire and for cutting the wire and stripping insulation therefrom comprising first structure operable to mark the wire; second structure operable to cut the marked wire and to strip insulation from the wire; the wire extending between and movable between the first and second structures, the first and second structure comprising separate stand-alone devices; and control structure, including external computer means, operatively connected with the first and second structures for controlling operation of the first and second structures in time sequence relation to wire movement therebetween, and/or to control wire marking, wire cutting, and insulation stripping length. 
",NAZERIAN GREG;;BAILEY RONALD;;HOFFA JACK L.,NAZERIAN GREG;;BAILEY RONALD;;HOFFA JACK L,,https://lens.org/092-861-182-497-312,Patent Application,yes,0,8,4,38,0,H02G1/1256;;H02G1/1256;;Y10T29/49117;;Y10T29/49117;;Y10T29/5193;;Y10T29/5193;;Y10T29/53209;;Y10T29/53209,H02G1/12,700/114;;X029;;700/125;;700/167,0,0,,,,DISCONTINUED
18,US,B2,US 8475624 B2,059-324-508-423-330,2013-07-02,2013,US 69769507 A,2007-04-06,US 69769507 A;;US 23732705 A;;US 44056106 A,2005-09-27,Method and system for distributing gas for a bevel edge etcher,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the top edge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrate is also provided.,SEXTON GREG;;BAILEY III ANDREW;;SCHOEN ALAN;;LAM RES CORP,SEXTON GREG;;BAILEY III ANDREW;;SCHOEN ALAN,LAM RESEARCH CORPORATION (2007-03-30),https://lens.org/059-324-508-423-330,Granted Patent,yes,10,3,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,C23F1/00;;B44C1/22;;C03C15/00;;C03C25/68;;H01L21/306,156/345.3;;156/345.43;;216/67,0,0,,,,ACTIVE
19,US,A1,US 2010/0179819 A1,014-454-272-442-019,2010-07-15,2010,US 35160109 A,2009-01-09,US 35160109 A,2009-01-09,MOBILE DISCRETE DATA DOCUMENTATION,"Systems, methods, and computer-readable media for transferring data from a medical device to a patient's electronic medical record are provided. Initially, a medical device and a patient are identified, such as by scanning a barcode or searching in an electronically-searchable database. Once identified, the medical device and the patient area associated, and data from the medical device is acquired and sent to a form that allows a user to edit the data or add other information. The user may then indicate that the data is ready to be transmitted to the patient's electronic medical record. The medical device and the patient may now be disassociated. The disassociation may be implicit, so that it is not required that a user provide an indication that the patient and medical device are to be disassociated. Rather, the disassociation may occur upon transmittal of the data to the patient's EMR.",CERNER INNOVATION INC,HERBST DAMON;;LANTZ RANDY;;MEYER GREG;;BAILEY MATT,CERNER INNOVATION INC (2009-01-12),https://lens.org/014-454-272-442-019,Patent Application,yes,7,38,6,8,0,G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67;;G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67,G06Q50/00;;G16H10/60;;G16H40/67,705/2,0,0,,,,ACTIVE
20,US,B2,US 10494817 B2,164-156-157-777-650,2019-12-03,2019,US 201715457910 A,2017-03-13,US 201715457910 A;;US 201514802205 A,2015-07-17,Retractable canopy,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,,https://lens.org/164-156-157-777-650,Granted Patent,yes,25,3,4,4,0,E04H15/644;;E04F10/02;;E04H15/58;;E04F10/0607;;E04H15/32;;E06B2009/2622;;E04F10/0607;;E04H15/644;;E04F10/02;;E06B9/24;;E06B9/58;;E06B9/581;;E06B9/80;;E06B2009/2423;;E04H15/02;;E04H15/58;;E04H15/64,E04F10/02;;E04F10/06;;E04H15/02;;E04H15/32;;E04H15/58;;E04H15/64;;E06B9/24;;E06B9/262;;E06B9/58;;E06B9/80,,0,0,,,,ACTIVE
21,CA,A1,CA 3156950 A1,140-381-578-478-712,2017-01-17,2017,CA 3156950 A,2015-07-17,CA 3156950 A;;CA 2897781 A,2015-07-17,RETRACTABLE CANOPY,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,,https://lens.org/140-381-578-478-712,Patent Application,no,0,0,4,4,0,E04H15/54;;E04H15/58;;E04H15/644;;E04F10/02;;E04F10/0607,,,0,0,,,,PENDING
22,US,B2,US 9624689 B2,022-325-510-239-251,2017-04-18,2017,US 201514802205 A,2015-07-17,US 201514802205 A,2015-07-17,Retractable canopy,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,OUTDOOR LIVING MANUFACTURING LTD (2015-09-21),https://lens.org/022-325-510-239-251,Granted Patent,yes,21,25,4,4,0,E04H15/644;;E04F10/02;;E04H15/58;;E04F10/0607;;E04H15/32;;E06B2009/2622;;E04F10/0607;;E04H15/644;;E04F10/02;;E06B9/24;;E06B9/58;;E06B9/581;;E06B9/80;;E06B2009/2423;;E04H15/02;;E04H15/58;;E04H15/64,E04H15/32;;E06B9/24;;E06B9/262;;E06B9/58;;E06B9/80,,0,0,,,,ACTIVE
23,US,A9,US 2017/0316160 A9,126-858-755-096-108,2017-11-02,2017,US 201615246971 A,2016-08-25,US 201615246971 A;;US 201414262110 A;;US 35160109 A,2009-01-09,MOBILE DISCRETE DATA DOCUMENTATION,"A medical device for facilitating data direction to storage in a patient-specific electronic record is provided herein. In embodiments, the medical device visually presents patient data received from devices that more directly capture physiological data. The medical device is associated with a patient corresponding to the physiological data, and communicates the patient data to a centralized server for processing and forwarding to a database, which includes an electronic record that is specific to the patient. Then, the medical device may be dissociated from the patient.",CERNER INNOVATION INC,HERBST DAMON;;LANTZ RANDY;;MEYER GREG;;BAILEY MATT,CERNER INNOVATION INC (2009-01-12),https://lens.org/126-858-755-096-108,Amended Application,yes,0,2,6,8,0,G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67;;G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67,G06Q10/10;;G16H10/60;;G16H40/67,,0,0,,,,ACTIVE
24,US,A1,US 2013/0276821 A1,121-765-611-143-820,2013-10-24,2013,US 201313933515 A,2013-07-02,US 201313933515 A;;US 69769507 A;;US 23732705 A;;US 44056106 A,2005-09-27,Method and System for Distributing Gas for A Bevel Edge Etcher,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the top edge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrate is also provided.,LAM RES CORP,SEXTON GREG;;BAILEY III ANDREW D;;SCHOEPP ALAN,,https://lens.org/121-765-611-143-820,Patent Application,yes,2,2,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,H01L21/02,134/1.2,0,0,,,,ACTIVE
25,US,A1,US 2017/0183876 A1,078-147-774-288-033,2017-06-29,2017,US 201715457910 A,2017-03-13,US 201715457910 A;;US 201514802205 A,2015-07-17,RETRACTABLE CANOPY,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,,https://lens.org/078-147-774-288-033,Patent Application,yes,0,10,4,4,0,E04H15/644;;E04F10/02;;E04H15/58;;E04F10/0607;;E04H15/32;;E06B2009/2622;;E04F10/0607;;E04H15/644;;E04F10/02;;E06B9/24;;E06B9/58;;E06B9/581;;E06B9/80;;E06B2009/2423;;E04H15/02;;E04H15/58;;E04H15/64,E04F10/02;;E04H15/02;;E04H15/58;;E04H15/64,,0,0,,,,ACTIVE
26,CA,C,CA 2897781 C,178-435-411-674-797,2022-07-12,2022,CA 2897781 A,2015-07-17,CA 2897781 A,2015-07-17,RETRACTABLE CANOPY,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,,https://lens.org/178-435-411-674-797,Granted Patent,no,0,0,4,4,0,E04H15/54;;E04H15/58;;E04H15/644;;E04F10/02;;E04F10/0607,E04H15/54;;E04H15/64,,0,0,,,,PENDING
27,US,A1,US 2016/0364530 A1,000-456-663-519-205,2016-12-15,2016,US 201615246971 A,2016-08-25,US 201615246971 A;;US 201414262110 A;;US 35160109 A,2009-01-09,MOBILE DISCRETE DATA DOCUMENTATION,"A medical device for facilitating data direction to storage in a patient-specific electronic record is provided herein. In embodiments, the medical device visually presents patient data received from devices that more directly capture physiological data. The medical device is associated with a patient corresponding to the physiological data, and communicates the patient data to a centralized server for processing and forwarding to a database, which includes an electronic record that is specific to the patient. Then, the medical device may be dissociated from the patient.",CERNER INNOVATION INC,HERBST DAMON;;LANTZ RANDY;;MEYER GREG;;BAILEY MATT,,https://lens.org/000-456-663-519-205,Patent Application,yes,0,2,6,8,0,G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67;;G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67,G16H10/60;;G16H40/67,,0,0,,,,ACTIVE
28,CA,A1,CA 2897781 A1,057-255-369-968-306,2017-01-17,2017,CA 2897781 A,2015-07-17,CA 2897781 A,2015-07-17,RETRACTABLE CANOPY,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,,https://lens.org/057-255-369-968-306,Patent Application,no,0,2,4,4,0,E04H15/54;;E04H15/58;;E04H15/644;;E04F10/02;;E04F10/0607,E04H15/54;;E04H15/64,,0,0,,,,PENDING
29,US,B2,US 8940098 B2,140-874-449-174-355,2015-01-27,2015,US 201313933515 A,2013-07-02,US 201313933515 A;;US 69769507 A;;US 23732705 A;;US 44056106 A,2005-09-27,Method for distributing gas for a bevel etcher,A plasma etch processing chamber configured to clean a bevel edge of a substrate is provided. The chamber includes a bottom edge electrode and a top edge electrode defined over the bottom edge electrode. The top edge electrode and the bottom edge electrode are configured to generate a cleaning plasma to clean the bevel edge of the substrate. The chamber includes a gas feed defined through a top surface of the processing chamber. The gas feed introduces a processing gas for striking the cleaning plasma at a location in the processing chamber that is between an axis of the substrate and the top edge electrode. A pump out port is defined through the top surface of the chamber and the pump out port located along a center axis of the substrate. A method for cleaning a bevel edge of a substrate is also provided.,LAM RES CORP,SEXTON GREG;;BAILEY III ANDREW D;;SCHOEPP ALAN,,https://lens.org/140-874-449-174-355,Granted Patent,yes,2,0,10,10,0,B08B7/0035;;B08B7/0035;;H01L21/02087;;H01L21/02087;;H01L21/3065;;H01J37/32009;;H01J37/32009;;H01J37/3244;;H01J37/3244;;H01J37/32706;;H01J37/32706;;Y10S134/902;;Y10S134/902,B08B5/00;;B08B7/00;;H01J37/32;;H01L21/02,134/1.2;;134/902;;216/67,0,0,,,,ACTIVE
30,CA,C,CA 3156950 C,037-523-072-350-831,2024-01-02,2024,CA 3156950 A,2015-07-17,CA 3156950 A;;CA 2897781 A,2015-07-17,RETRACTABLE CANOPY,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,,https://lens.org/037-523-072-350-831,Granted Patent,no,0,0,4,4,0,E04H15/54;;E04H15/58;;E04H15/644;;E04F10/02;;E04F10/0607,E04H15/54;;E04F10/02;;E04H15/64,,0,0,,,,PENDING
31,US,A1,US 2017/0016245 A1,095-443-881-435-302,2017-01-19,2017,US 201514802205 A,2015-07-17,US 201514802205 A,2015-07-17,RETRACTABLE CANOPY,"Aspects of the present disclosure provide retractable canopies, kits of parts for assembling retractable canopies, and methods for assembling and operating retractable canopies. The retractable canopies provide tracks extending in a longitudinal direction and transversely spaced apart. A support extends in a transverse direction between the tracks and is moveably coupled to the tracks via mounts to the tracks. The mounts include engagement members, such as wheels, to engage with the tracks. The engagement members may be biased transversely away from the support (e.g. toward the track), thereby permitting the engagement members to adjust their transverse positions relative to the support as the support moves along the track.",OUTDOOR LIVING MFG LTD,BAILEY GREG;;BROWN TERRY JAMES;;BARRON ANDREW JOHN,OUTDOOR LIVING MANUFACTURING LTD (2015-09-21),https://lens.org/095-443-881-435-302,Patent Application,yes,0,9,4,4,0,E04H15/644;;E04F10/02;;E04H15/58;;E04F10/0607;;E04H15/32;;E06B2009/2622;;E04F10/0607;;E04H15/644;;E04F10/02;;E06B9/24;;E06B9/58;;E06B9/581;;E06B9/80;;E06B2009/2423;;E04H15/02;;E04H15/58;;E04H15/64,E04H15/32;;E06B9/24;;E06B9/58;;E06B9/80,,0,0,,,,ACTIVE
32,US,A1,US 2014/0236634 A1,124-225-601-855-324,2014-08-21,2014,US 201414262110 A,2014-04-25,US 201414262110 A;;US 35160109 A,2009-01-09,MOBILE DISCRETE DATA DOCUMENTATION,"Systems, methods, and computer-readable media for transferring data from a medical device to a patient's electronic medical record are provided. Initially, a medical device and a patient are identified, such as by scanning a barcode or searching in an electronically-searchable database. Once identified, the medical device and the patient area associated, and data from the medical device is acquired and sent to a form that allows a user to edit the data or add other information. The user may then indicate that the data is ready to be transmitted to the patient's electronic medical record. The medical device and the patient may now be disassociated. The disassociation may be implicit, so that it is not required that a user provide an indication that the patient and medical device are to be disassociated. Rather, the disassociation may occur upon transmittal of the data to the patient's EMR.",CERNER INNOVATION INC,HERBST DAMON;;LANTZ RANDY;;MEYER GREG;;BAILEY MATT,CERNER INNOVATION INC (2009-01-12),https://lens.org/124-225-601-855-324,Patent Application,yes,16,5,6,8,0,G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67;;G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67,G16H10/60;;G16H40/67,705/3,0,0,,,,DISCONTINUED
33,US,B2,US 8731957 B2,089-185-690-398-792,2014-05-20,2014,US 35160109 A,2009-01-09,US 35160109 A,2009-01-09,Mobile discrete data documentation,"Systems, methods, and computer-readable media for transferring data from a medical device to a patient's electronic medical record are provided. Initially, a medical device and a patient are identified, such as by scanning a barcode or searching in an electronically-searchable database. Once identified, the medical device and the patient area associated, and data from the medical device is acquired and sent to a form that allows a user to edit the data or add other information. The user may then indicate that the data is ready to be transmitted to the patient's electronic medical record. The medical device and the patient may now be disassociated. The disassociation may be implicit, so that it is not required that a user provide an indication that the patient and medical device are to be disassociated. Rather, the disassociation may occur upon transmittal of the data to the patient's EMR.",HERBST DAMON;;LANTZ RANDY;;MEYER GREG;;BAILEY MATT;;CERNER INNOVATION INC,HERBST DAMON;;LANTZ RANDY;;MEYER GREG;;BAILEY MATT,CERNER INNOVATION INC (2009-01-12),https://lens.org/089-185-690-398-792,Granted Patent,yes,7,7,6,8,0,G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67;;G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67,G06Q50/00;;G16H10/60;;G16H40/67,705/2,1,0,,,"WO 2006/035351 to Baldus et al. ""System for Automatic Continuous and Reliable Patient Identification for Association of Wireless Medical Devices to Patients"" Apr. 6, 2006.",ACTIVE
34,BR,A2,BR PI0917743 A2,001-051-357-737-192,2016-07-26,2016,BR PI0917743 A,2009-11-03,US 2009/0063104 W;;US 33400608 A,2008-12-12,"unidade de processamento de sólidos submarinos, aparelho de perfuração de gradiente duplo, método para recuperar lama de perfuração e método para controlar uma unidade de processamento de sólidos submarinos",,HYDRIL USA MFG LLC,NGUYEN DAT;;BAILEY GREG;;HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD,,https://lens.org/001-051-357-737-192,Patent Application,no,0,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,,0,0,,,,DISCONTINUED
35,GB,A,GB 2417311 A,100-186-340-792-643,2006-02-22,2006,GB 0523727 A,2004-06-03,US 2004/0017563 W;;US 47580903 P,2003-06-03,Systems and methods for providing a haptic manipulandum,"Systems and methods for providing a haptic manipulandum are described. In one described system, a lever arm is pivotably coupled to a housing, and configured to apply a processor-controlled force to a substantially-spherical manipulandum to provide a haptic effect. The described system may include a processor in communication with an actuator for providing the haptic effect.",IMMERSION CORP,ANASTAS GEORGE V;;BAILEY DAVID W;;TASHJIAN GREG;;YU RAYMOND,,https://lens.org/100-186-340-792-643,Patent Application,no,7,0,10,10,0,G06F3/016;;G06F3/016;;G06F3/03549;;G06F3/03549,G06F3/00;;G06F3/01;;G06F3/033;;G09G5/08,F2Y YSK           Z;;F2Y YSN           Z;;F2Y YSW           Z;;F2Y YSX           Z;;F2Y Y3103         Z;;U1S S1172;;U1S S2116;;U1S S2215;;U1S S2222;;U1S S2424,0,0,,,,INACTIVE
36,WO,A2,WO 2010/068347 A2,106-182-413-043-943,2010-06-17,2010,US 2009/0063104 W,2009-11-03,US 33400608 A,2008-12-12,SUBSEA SOLIDS PROCESSING APPARATUSES AND METHODS,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HYDRIL USA MFG LLC;;HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/106-182-413-043-943,Patent Application,yes,0,1,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,,0,0,,,,PENDING
37,US,B2,US 8511402 B2,181-765-427-879-973,2013-08-20,2013,US 201213419028 A,2012-03-13,US 201213419028 A;;US 33400608 A,2008-12-12,Subsea solids processing apparatuses and methods,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG;;HYDRIL USA MFG LLC,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/181-765-427-879-973,Granted Patent,yes,15,4,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B7/00;;B02C4/32,175/57;;241/35,1,0,,,"PCT/US2009/063104, Search Report and Written Opinion, May 31, 2010.",INACTIVE
38,US,B2,US 8157014 B2,082-724-568-488-28X,2012-04-17,2012,US 33400608 A,2008-12-12,US 33400608 A,2008-12-12,Subsea solids processing apparatuses and methods,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG;;HYDRIL USA MFG LLC,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,HYDRIL USA MANUFACTURING LLC (2009-04-07),https://lens.org/082-724-568-488-28X,Granted Patent,yes,19,21,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B43/36;;B02C23/00;;E21B7/12,166/357;;166/358;;241/236;;241/46.06,9,5,149-918-206-029-240;;091-522-892-464-934;;082-340-181-029-529;;079-933-960-989-17X;;176-726-740-265-879,10.2118/58793-ms;;10.2118/29424-ms;;10.2118/14178-pa;;10.2118/9701-pa;;10.2118/22578-ms,"Dick, M.A., Heinz, T.J., Svoboda, C.F., Aston, M., ""Optimizing the Selection of Bridging Particles for Reservoir Drilling Fluids"", SPE International Symposium on Formation Damage, Lafayette, LA., USA, Feb. 23-24, 2000.;;Van Oort, E., Hale, A.H., Mody, F.K. and Roy, S., ""Critical Parameters in Modelling the Chemical Aspects of Borehold Stability in Shales and in Designing Improved Water-Based Shale Drilling Fluids"", SPE Annual Technical Conference and Exhibition, New Orleans, LA, USA, Sep. 25-28, 1994.;;Hale, A.H., Albrecht, M.S., Roy, S., Dzialowski, A. and Mody, F.K., ""Preliminary Report on Effectiveness of Different Lubricants on Wear and Friction Coefficient Using Shale Medium"", SPE/IADC Drilling Conference, Amsterdam, Feb. 28-Mar. 2, 1995 pp. 171-186.;;""Operation and Maintenance Manual"" (Rev. 0), TM2300 Taskmaster, Sub-Sea Crusher (Document OM00160A), Franklin Miller, Inc., Livingston, NJ, Apr. 24, 2001.;;Bourgoyne, A.T., Chenevert, M.E., Millheim, K.K. and Young, F.S., ""Applied Drilling Engineering"", SPE Textbook Series, vol. 2, Society of Petroleum Engineers, Richardson, TX 1986 Chapter 4, pp. 156-157.;;Okrajni, S. and Azar, J.J., ""The Effects of Mud Rheology on Annular Hole Cleaning in Directional Wells"", (SPE 14178), Society of Petroleum Engineers Drilling Engineering (SPEDE) Journal, Aug. 1986 pp. 297-308.;;Azar, J.J. and Becker, T.E., Thomas, R. P., ""Drillpipe Eccentricity Effect on Drilled Cuttings Behavior in Vertical Wellbores"", (SPE 9701), Journal of Petroleum Technology, Sep. 1982.;;Ledgerwood III, L.W., and Salisbury, D.P., ""Bit Balling and Wellbore Instability of Downhole Shales"", (SPE 22578), SPE Annual Technical Conference and Exhibition, Dallas, TX, USA 1991.;;PCT/US2009/063104, Search Report and Written Opinion, May 31, 2010.",INACTIVE
39,US,A1,US 2019/0114707 A1,082-181-169-937-959,2019-04-18,2019,US 201715785356 A,2017-10-16,US 201715785356 A,2017-10-16,Distribution of Blockchain Tokens,"Disclosed herein are system, method, and computer program product embodiments for introducing and removing blockchain based cryptocurrency tokens based on usage and demand for the cryptocurrency. An embodiment operates by transmitting, to a peer-to-peer network of computing devices configured to store a blockchain of processes, instructions for execution by one or more devices of the peer-to-peer network. The instructions comprise determining a rate of change associated with an exchange price of a cryptocurrency token. The instructions further include receiving an indication that a first amount of cryptocurrency tokens has been transferred to a recipient address of a plurality of addresses and generating a second amount of cryptocurrency tokens based on the first amount of cryptocurrency tokens that has been transferred and on the determined rate of change of the exchange price associated with the cryptocurrency token. The second amount of cryptocurrency tokens is allocated to the recipient address.",SHINESTACK LLC,MCSHEEHAN KEVIN;;JACKSON COREY;;STEINBUKS JEVJENIJS;;FORSTER ROBERT;;BAILEY GREG,,https://lens.org/082-181-169-937-959,Patent Application,yes,0,15,1,1,0,G06Q40/04;;G06Q2220/00;;G06Q20/381;;G06Q20/065;;G06Q40/04;;G06Q20/223;;G06Q2220/00;;G06Q20/3829;;G06Q20/3827;;G06Q20/0658;;G06Q20/381;;G06Q20/065,G06Q40/04;;G06Q20/06;;G06Q20/22;;G06Q20/38,,0,0,,,,DISCONTINUED
40,CN,B,CN 101606233 B,119-611-992-712-80X,2011-07-27,2011,CN 200880004384 A,2008-02-05,US 2008/0053081 W;;US 67292207 A,2007-02-08,Bevel clean device,"An apparatus for removing material on a bevel of a wafer is provided. A wafer support with a diameter that is less than the diameter of the wafer, wherein the wafer support is on a first side of the wafer, and wherein an outer edge of the wafer extends beyond the wafer support around the wafer is provided. An RF power source is electrically connected to the wafer. A central cover is spaced apart from the wafer support. A first electrically conductive ring is on the first side of and spaced apart from the wafer. A second electrically conductive ring is spaced apart from the wafer. An electrically conductive liner surrounds the outer edge of the wafer. A switch is between the liner and ground, allowing the liner to be switched from being grounded to floating.",LAM RESERCH CORP,YUNSANG KIM;;ANDREW BAILEY;;GREG SEXTON;;KEECHAN KIM;;ANDRAS KUTHI,,https://lens.org/119-611-992-712-80X,Granted Patent,no,0,0,13,13,0,H01L21/02087;;H01L21/02087;;H01L21/3065,H01L21/3065,,0,0,,,,ACTIVE
41,US,A1,US 2012/0228030 A1,045-588-543-761-491,2012-09-13,2012,US 201213419028 A,2012-03-13,US 201213419028 A;;US 33400608 A,2008-12-12,Subsea Solids Processing Apparatuses and Methods,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG;;GE OIL & GAS HYDRIL USA,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/045-588-543-761-491,Patent Application,yes,0,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06;;E21B7/00,175/57;;175/207,0,0,,,,INACTIVE
42,EP,A4,EP 2376739 A4,082-759-716-237-475,2017-10-25,2017,EP 09832288 A,2009-11-03,US 2009/0063104 W;;US 33400608 A,2008-12-12,SUBSEA SOLIDS PROCESSING APPARATUSES AND METHODS,,HYDRIL USA MFG LLC,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/082-759-716-237-475,Search Report,no,10,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06;;B02C13/20;;E21B21/00,,0,0,,,,DISCONTINUED
43,SG,A1,SG 172053 A1,156-004-098-856-080,2011-07-28,2011,SG 2011042116 A,2009-11-03,US 33400608 A;;US 2009/0063104 W,2008-12-12,SUBSEA SOLIDS PROCESSING APPARATUSES AND METHODS,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HYDRIL USA MFG LLC,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/156-004-098-856-080,Patent Application,no,0,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,,,0,0,,,,PENDING
44,WO,A3,WO 2010/068347 A3,173-089-176-085-616,2010-08-05,2010,US 2009/0063104 W,2009-11-03,US 33400608 A,2008-12-12,SUBSEA SOLIDS PROCESSING APPARATUSES AND METHODS,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HYDRIL USA MFG LLC;;HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/173-089-176-085-616,Search Report,yes,5,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,,0,0,,,,PENDING
45,AU,A1,AU 2009/325030 A1,086-916-722-270-142,2011-07-07,2011,AU 2009/325030 A,2009-11-03,US 33400608 A;;US 2009/0063104 W,2008-12-12,Subsea solids processing apparatuses and methods,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HYDRIL USA MFG LLC,RAMAN HARIHARAN PERINGANDOOR;;ARNOLD JUDGE ROBERT;;DAT NGUYEN;;GREG BAILEY,,https://lens.org/086-916-722-270-142,Patent Application,no,0,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,,0,0,,,,INACTIVE
46,EP,A2,EP 2376739 A2,025-073-917-470-640,2011-10-19,2011,EP 09832288 A,2009-11-03,US 2009/0063104 W;;US 33400608 A,2008-12-12,SUBSEA SOLIDS PROCESSING APPARATUSES AND METHODS,,HYDRIL USA MFG LLC,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/025-073-917-470-640,Patent Application,yes,0,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,,0,0,,,,DISCONTINUED
47,US,A1,US 2008/0190448 A1,083-332-469-741-028,2008-08-14,2008,US 67292207 A,2007-02-08,US 67292207 A,2007-02-08,BEVEL CLEAN DEVICE,"An apparatus for removing material on a bevel of a wafer is provided. A wafer support with a diameter that is less than the diameter of the wafer, wherein the wafer support is on a first side of the wafer, and wherein an outer edge of the wafer extends beyond the wafer support around the wafer is provided. An RF power source is electrically connected to the wafer. A central cover is spaced apart from the wafer support. A first electrically conductive ring is on the first side of and spaced apart from the wafer. A second electrically conductive ring is spaced apart from the wafer. An electrically conductive liner surrounds the outer edge of the wafer. A switch is between the liner and ground, allowing the liner to be switched from being grounded to floating.",LAM RES CORP,KIM YUNSANG;;BAILEY ANDREW;;SEXTON GREG;;KIM KEECHAN;;KUTHI ANDRAS,LAM RESEARCH CORPORATION (2007-02-07),https://lens.org/083-332-469-741-028,Patent Application,yes,10,13,13,13,0,H01L21/02087;;H01L21/02087;;H01L21/3065,B08B6/00,134/1.1;;134/198,0,0,,,,ACTIVE
48,US,A1,US 2010/0147593 A1,158-323-957-247-226,2010-06-17,2010,US 33400608 A,2008-12-12,US 33400608 A,2008-12-12,Subsea Solids Processing Apparatuses and Methods,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,HYDRIL USA MANUFACTURING LLC (2009-04-07),https://lens.org/158-323-957-247-226,Patent Application,yes,19,15,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,175/66;;175/207,0,0,,,,INACTIVE
49,GB,B,GB 2417311 B,126-307-158-799-779,2007-05-09,2007,GB 0523727 A,2004-06-03,US 2004/0017563 W;;US 47580903 P,2003-06-03,Systems and methods for providing a haptic manipulandum,,IMMERSION CORP,ANASTAS GEORGE V;;BAILEY DAVID W;;TASHJIAN GREG;;YU RAYMOND,,https://lens.org/126-307-158-799-779,Granted Patent,no,7,0,10,10,0,G06F3/016;;G06F3/016;;G06F3/03549;;G06F3/03549,G06F3/00;;G06F3/01;;G06F3/033;;G09G5/08,F2Y YSK           Z;;F2Y YSN           Z;;F2Y YSW           Z;;F2Y YSX           Z;;F2Y Y3103         Z;;U1S S1172;;U1S S2116;;U1S S2215;;U1S S2222;;U1S S2424,0,0,,,,INACTIVE
50,CN,A,CN 101606233 A,150-939-775-563-599,2009-12-16,2009,CN 200880004384 A,2008-02-05,US 2008/0053081 W;;US 67292207 A,2007-02-08,Bevel clean device,"An apparatus for removing material on a bevel of a wafer is provided. A wafer support with a diameter that is less than the diameter of the wafer, wherein the wafer support is on a first side of the wafer, and wherein an outer edge of the wafer extends beyond the wafer support around the wafer is provided. An RF power source is electrically connected to the wafer. A central cover is spaced apart from the wafer support. A first electrically conductive ring is on the first side of and spaced apart from the wafer. A second electrically conductive ring is spaced apart from the wafer. An electrically conductive liner surrounds the outer edge of the wafer. A switch is between the liner and ground, allowing the liner to be switched from being grounded to floating.",LAM RES CORP,YUNSANG KIM;;ANDREW BAILEY;;GREG SEXTON;;KEECHAN KIM;;ANDRAS KUTHI,,https://lens.org/150-939-775-563-599,Patent Application,no,0,3,13,13,0,H01L21/02087;;H01L21/02087;;H01L21/3065,H01L21/3065,,0,0,,,,ACTIVE
51,WO,A1,WO 2004/111818 A1,021-557-433-650-560,2004-12-23,2004,US 2004/0017563 W,2004-06-03,US 47580903 P,2003-06-03,SYSTEMS AND METHODS FOR PROVIDING A HAPTIC MANIPULANDUM,"Systems and methods for providing a haptic manipulandum are described. In one described system, a lever arm is pivotably coupled to a housing, and configured to apply a processor-controlled force to a substantially-spherical manipulandum to provide a haptic effect. The described system may include a processor in communication with an actuator for providing the haptic effect.",IMMERSION CORP;;ANASTAS GEORGE V;;BAILEY DAVID W;;TASHJIAN GREG;;YU RAYMOND,ANASTAS GEORGE V;;BAILEY DAVID W;;TASHJIAN GREG;;YU RAYMOND,,https://lens.org/021-557-433-650-560,Patent Application,yes,7,8,10,10,0,G06F3/016;;G06F3/016;;G06F3/03549;;G06F3/03549,G06F3/00;;G06F3/01;;G06F3/033;;G09G5/08,,0,0,,,,PENDING
52,AU,B2,AU 2009/325030 B2,022-136-733-234-471,2016-03-17,2016,AU 2009/325030 A,2009-11-03,US 33400608 A;;US 2009/0063104 W,2008-12-12,Subsea solids processing apparatuses and methods,"In a dual-gradient drilling apparatus, a subsea solids processing unit includes a housing, a solids processing mechanism disposed in the housing between a drilling mud inlet and a drilling mud outlet, and a flushing mechanism configured to flush the solids processing mechanism with a flushing fluid. A subsea solids processing unit may be controlled by rotating the solids processing mechanism in a forward direction and increasing a drive torque when a measured speed of the solids processing mechanism is below a desired rotation speed. The desired rotation speed may be decreased when a measured torque exceeds a selected maximum and a rotation direction of the solids processing mechanism may be reversed when the measured speed falls below a selected minimum.",HYDRIL USA MFG LLC,HARIHARAN PERINGANDOOR RAMAN;;JUDGE ROBERT ARNOLD;;NGUYEN DAT;;BAILEY GREG,,https://lens.org/022-136-733-234-471,Granted Patent,no,5,0,12,12,0,E21B21/001;;E21B21/066;;B02C18/142;;E21B21/066;;E21B21/001,E21B21/06,,0,0,,,,INACTIVE
53,JP,A,JP 2013145884 A,163-049-905-646-593,2013-07-25,2013,JP 2013005371 A,2013-01-16,US 67292207 A,2007-02-08,BEVEL CLEAN DEVICE AND METHOD,"PROBLEM TO BE SOLVED: To provide a device for removing material on a bevel of a wafer.SOLUTION: A wafer support 104 with a diameter that is less than a diameter of a wafer 110 is provided. The wafer support is located on a first side of the wafer, and an outer edge of the wafer extends beyond the wafer support around the wafer. An RF power source 112 is electrically connected to the wafer. A central cover 103 is spaced apart from the wafer support. A first electrically conductive ring 124 is located on the first side of and spaced apart from the wafer. A second electrically conductive ring 132 is spaced apart from the wafer. An electrically conductive liner 144 surrounds the outer edge of the wafer. A switch 148 is located between the liner and ground, allowing the liner to be switched from being grounded to floating.",LAM RES CORP,KIM YUNSANG;;ANDREW BAILEY III;;GREG SEXTON;;KIM KEECHAN;;ANDRAS KUTHI,,https://lens.org/163-049-905-646-593,Patent Application,no,4,2,13,13,0,H01L21/02087;;H01L21/02087;;H01L21/3065,H01L21/3065;;H05H1/46,,0,0,,,,ACTIVE
54,US,B2,US 8137501 B2,119-322-905-335-305,2012-03-20,2012,US 67292207 A,2007-02-08,US 67292207 A,2007-02-08,Bevel clean device,"An apparatus for removing material on a bevel of a wafer is provided. A wafer support with a diameter that is less than the diameter of the wafer, wherein the wafer support is on a first side of the wafer, and wherein an outer edge of the wafer extends beyond the wafer support around the wafer is provided. An RF power source is electrically connected to the wafer. A central cover is spaced apart from the wafer support. A first electrically conductive ring is on the first side of and spaced apart from the wafer. A second electrically conductive ring is spaced apart from the wafer. An electrically conductive liner surrounds the outer edge of the wafer. A switch is between the liner and ground, allowing the liner to be switched from being grounded to floating.",KIM YUNSANG;;BAILEY III ANDREW;;SEXTON GREG;;KIM KEECHAN;;KUTHI ANDRAS;;LAM RES CORP,KIM YUNSANG;;BAILEY III ANDREW;;SEXTON GREG;;KIM KEECHAN;;KUTHI ANDRAS,LAM RESEARCH CORPORATION (2007-02-07),https://lens.org/119-322-905-335-305,Granted Patent,yes,13,5,13,13,0,H01L21/02087;;H01L21/02087;;H01L21/3065,C23C16/00;;C23F1/00;;H01L21/306,156/345.51;;118/715;;118/728;;156/345.45,5,0,,,"International Search Report dated Jun. 25, 2008 from International Application No. PCT/US2008/053081.;;Written Opinion dated Jun. 25, 2008 from International Application No. PCT/US2008/053081.;;Office Action dated Aug. 30, 2010 from Chinese Application No. 200880004384.7.;;Search Report dated Jan. 4, 2011 from Singapore Patent Application No. 200905165-7.;;Examination Report dated Jan. 4, 2011 from Singapore Patent Application No. 200905165-7.",ACTIVE
55,WO,A1,WO 2008/097996 A1,085-162-838-004-917,2008-08-14,2008,US 2008/0053081 W,2008-02-05,US 67292207 A,2007-02-08,BEVEL CLEAN DEVICE,"An apparatus for removing material on a bevel of a wafer is provided. A wafer support with a diameter that is less than the diameter of the wafer, wherein the wafer support is on a first side of the wafer, and wherein an outer edge of the wafer extends beyond the wafer support around the wafer is provided. An RF power source is electrically connected to the wafer. A central cover is spaced apart from the wafer support. A first electrically conductive ring is on the first side of and spaced apart from the wafer. A second electrically conductive ring is spaced apart from the wafer. An electrically conductive liner surrounds the outer edge of the wafer. A switch is between the liner and ground, allowing the liner to be switched from being grounded to floating.",LAM RES CORP;;KIM YUNSANG;;BAILEY ANDREW III;;SEXTON GREG;;KIM KEECHAN;;KUTHI ANDRAS,KIM YUNSANG;;BAILEY ANDREW III;;SEXTON GREG;;KIM KEECHAN;;KUTHI ANDRAS,,https://lens.org/085-162-838-004-917,Patent Application,yes,4,3,13,13,0,H01L21/02087;;H01L21/02087;;H01L21/3065,H01L21/3065,,0,0,,,,PENDING
56,US,S,US D0803836 S,096-344-486-124-814,2017-11-28,2017,US 201629582307 F,2016-10-26,US 201629582307 F,2016-10-26,Keyboard,,MICROSOFT CORP,ZHENG MICHAEL;;JONES GREG;;RAKEN JAN;;BAILEY KATE;;YANG SHEAU JIUN,MICROSOFT CORPORATION (2016-10-07),https://lens.org/096-344-486-124-814,Design Right,no,0,1,2,2,0,,,1402;;D14/398,0,0,,,,ACTIVE
57,TW,B,TW I401339 B,044-234-628-251-621,2013-07-11,2013,TW 97103864 A,2008-02-01,US 70185407 A,2007-02-02,Apparatus for defining regions of process exclusion and process performance in a process chamber,,LAM RES CORP,BAILEY III ANDREW D;;CHEN JACK;;KIM YUNSANG;;SEXTO GREG S,,https://lens.org/044-234-628-251-621,Granted Patent,no,2,0,8,8,0,H01L21/302;;H01L21/67069;;H01L21/67069;;H01J37/32568;;H01J37/32568;;H01L21/02;;H01L21/683;;H01L21/68721;;H01L21/68721,,,0,0,,,,ACTIVE
58,US,S,US D0803835 S,121-990-264-464-814,2017-11-28,2017,US 201629582306 F,2016-10-26,US 201629582306 F,2016-10-26,Keyboard,,MICROSOFT CORP,ZHENG MICHAEL;;JONES GREG;;RAKEN JAN;;BAILEY KATE;;YANG SHEAU JIUN,MICROSOFT CORPORATION (2016-10-07),https://lens.org/121-990-264-464-814,Design Right,no,0,10,2,2,0,,,1402;;D14/398,0,0,,,,ACTIVE
59,US,B1,US 11037076 B1,099-946-605-590-955,2021-06-15,2021,US 201816122672 A,2018-09-05,US 201816122672 A;;US 201762554925 P,2017-09-06,Method and system for distributing electronic ticket status information for a live event over a network to a remote subscriber portable computing device,A method and system for distributing electronic ticket status information over a network to a remote subscriber portable computing device for a live event includes providing an electronic ticket manager application to a subscriber for installation on the remote subscriber portable computing device. Ticket data for the live event is received over the Internet with a transmission server which has a microprocessor and a memory that stores a remote subscriber's preferences for ticket information format and destination address. The microprocessor filters the ticket data based on past live events and other subscribers who have attended past live events with the subscriber in a group seating arrangement. The microprocessor generates an alert that activates the portable computing device to display a message that suggests the subscriber may attend the live event and invite other subscribers to sit with the subscriber at the event.,SOUTHERN EXPERIENCE LLC,SMITH KEVIN;;FOSTER GREG;;GASPARD JUNIOR;;BAILEY TRAVIS;;CABRERA RICK;;LECRAW CHRIS,SOUTHERN EXPERIENCE LLC (2019-02-22),https://lens.org/099-946-605-590-955,Granted Patent,yes,5,2,1,1,0,G06Q10/02;;G06Q10/02;;H04W4/021;;H04W4/021;;H04W4/21,G06Q10/02;;H04W4/021,,1,0,,,"TicketNews.com, “AXS Invite simplifies ticket purchasing with friends” available at: https://www.ticketnews.com/2012/10/axs-invite-simplifies-ticket-purchasing-with-friends/, last accessed Nov. 19, 2020 (Year: 2012).",ACTIVE
60,AU,A1,AU 2012/205243 A1,045-457-093-189-220,2013-01-31,2013,AU 2012/205243 A,2012-07-16,AU 2011/902831 A;;AU 2012/205243 A,2011-07-15,A System for Manufacturing a Container,"Abstract There is disclosed a system for manufacturing a container comprising a cylindrical wall. The system comprises a 5 container wall former adapted to receive a sheet of material. The container wall former comprises a series of container wall forming mechanisms adapted to form the cylindrical wall, by advancing the sheet along a helical path through the container wall forming mechanisms. The 10 system also comprises a system controller in data communication with each one of container wall forming mechanisms. The system controller is configured to receive a user input from a user input device, and, in response to receipt of the user input received by the is system controller, communicate with each one of the container wall forming mechanisms to control the container wall forming mechanisms to advance the sheet received by the container wall former along the helical path through the container wall forming mechanisms. 16/07/12 349013_ ( GHMaers) P87498AU",MR AND KL JAESCHKE PTY LTD,JAESCHKE MAURICE;;STUTE PETER;;HUNT GREG;;LEWIS BEN;;GILBERT DAMIEN;;BAILEY PETER,,https://lens.org/045-457-093-189-220,Patent Application,no,0,3,1,1,0,B21C37/12,B21D11/06,,0,0,,,,DISCONTINUED
61,US,B2,US 10593427 B2,077-250-336-429-165,2020-03-17,2020,US 201815918711 A,2018-03-12,US 201815918711 A;;US 201414262110 A;;US 35160109 A,2009-01-09,Mobile discrete data documentation,"A medical device for facilitating data direction to storage in a patient-specific electronic record is provided herein. In embodiments, the medical device visually presents patient data received from devices that more directly capture physiological data. The medical device is associated with a patient corresponding to the physiological data, and communicates the patient data to a centralized server for processing and forwarding to a database, which includes an electronic record that is specific to the patient. Then, the medical device may be dissociated from the patient.",CERNER INNOVATION INC,HERBST DAMON MATTHEW;;LANTZ RANDOLPH S;;MEYER GREG T;;BAILEY MATTHEW P,CERNER INNOVATION INC (2009-01-12),https://lens.org/077-250-336-429-165,Granted Patent,yes,43,0,2,8,0,G16H40/67;;G16H40/63;;G06Q10/10;;G16H10/60;;G16H40/63;;G06Q10/10;;G06Q50/22;;G16H10/60;;G16H40/67,G16H40/60;;G06Q10/10;;G06Q50/22;;G16H10/60;;G16H40/63;;G16H40/67,,10,1,074-050-087-196-616,18510408;;10.2345/0899-8205(2008)42[205:bditci]2.0.co;2,"Preinterview First Office Action received for U.S. Appl. No. 15/246,971, dated Jun. 5, 2019, 6 pages.;;Moorman, Bridget, Biomedical Device Interfacing to Clinical Information Systems: A Primer, Biomedical Instrumentation & Technology, IT World, pp. 205-208. Available at: https://rdcms-aami.s3.amazonaws.com/files/production/public/FileDownloads/BIT/2008_BIT_MJ_Medical_Device_Interfacing.pdf.;;Ganous et al., “A Pervasive Computing System for the Operating Room of the Future”, University of Maryland Medical School, 2007, 18 pages.;;Final Office Action dated Dec. 15, 2017 in U.S. Appl. No. 14/262,110, 13 pages.;;Final Office Action dated Sep. 29, 2011 in U.S. Appl. No. 12/351,601, 18 pages.;;Non-Final Office Action dated May 10, 2011 in U.S. Appl. No. 12/351,601, 16 pages.;;Final Office Action dated Jul. 31, 2012 in U.S. Appl. No. 12/351,601, 24 pages.;;Non-Final Office Action dated Feb. 28, 2012 in U.S. Appl. No. 12/351,601,23 pages.;;Notice of Allowance dated Jan. 9, 2014 in U.S. Appl. No. 12/351,601, 9 pages.;;Final Office Action dated Nov. 21, 2016 in U.S. Appl. No. 14/262,110, 33 pages.",ACTIVE
62,US,A1,US 2018/0204641 A1,162-270-132-503-668,2018-07-19,2018,US 201815918711 A,2018-03-12,US 201815918711 A;;US 201414262110 A;;US 35160109 A,2009-01-09,MOBILE DISCRETE DATA DOCUMENTATION,"A medical device for facilitating data direction to storage in a patient-specific electronic record is provided herein. In embodiments, the medical device visually presents patient data received from devices that more directly capture physiological data. The medical device is associated with a patient corresponding to the physiological data, and communicates the patient data to a centralized server for processing and forwarding to a database, which includes an electronic record that is specific to the patient. Then, the medical device may be dissociated from the patient.",CERNER INNOVATION INC,HERBST DAMON MATTHEW;;LANTZ RANDOLPH S;;MEYER GREG T;;BAILEY MATTHEW P,CERNER INNOVATION INC (2009-01-12),https://lens.org/162-270-132-503-668,Patent Application,yes,0,1,2,8,0,G16H40/67;;G16H40/63;;G06Q10/10;;G16H10/60;;G16H40/63;;G06Q10/10;;G06Q50/22;;G16H10/60;;G16H40/67,G16H40/63;;G06Q10/10;;G06Q50/22;;G16H10/60,,0,0,,,,ACTIVE
63,US,B2,US 10546357 B2,184-770-085-872-549,2020-01-28,2020,US 201615246971 A,2016-08-25,US 201615246971 A;;US 201414262110 A;;US 35160109 A,2009-01-09,Mobile discrete data documentation,"A device for facilitating data direction to storage in a patient-specific electronic record is provided herein. In embodiments, the device visually presents patient data received from devices that more directly capture physiological data. The device is associated with a patient corresponding to the physiological data, and communicates the patient data to a centralized server for processing and forwarding to a database, which includes an electronic record that is specific to the patient. Then, the device may be dissociated from the patient.",CERNER INNOVATION INC,HERBST DAMON MATTHEW;;LANTZ RANDOLPH S;;MEYER GREG T;;BAILEY MATTHEW P,CERNER INNOVATION INC (2009-01-12),https://lens.org/184-770-085-872-549,Granted Patent,yes,44,0,6,8,0,G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67;;G06Q10/10;;G16H40/63;;G16H10/60;;G16H40/67,G16H40/60;;G06Q10/10;;G16H10/60;;G16H40/67,,9,1,074-050-087-196-616,18510408;;10.2345/0899-8205(2008)42[205:bditci]2.0.co;2,"Final Office Action dated Nov. 21, 2016 in U.S. Appl. No. 14/262,110, 33 pages.;;Moorman, Bridget, “Biomedical Device Interfacing to Clinical Information Systems: A Primer”, Biomedical Instrumentation & Technology, IT World, pp. 205-208. Available at: https://rdcms-aami.s3.amazonaws.com/files/production/public/FileDownloads/BIT/2008_BIT_MJ_Medical_Device_Interfacing.pdf.;;Ganous et al., “A Pervasive Computing System for the Operating Room of the Future”, University of Maryland Medical School, 2007, 18 pages. Available at: https://ebiquity.umbc.edu/_file_directory_/papers/357.pdf.;;Final Office Action dated Dec. 15, 2017 in U.S. Appl. No. 14/262,110, 15 pages.;;Non-Final Office Action dated May 10, 2011 in U.S. Appl. No. 12/351,601, 16 pages.;;Final Office Action dated Sep. 29, 2011 in U.S. Appl. No. 12/351,601, 18 pages.;;Non-Final Office Action dated Feb. 28, 2012 in U.S. Appl. No. 12/351,601, 23 pages.;;Final Office Action dated Jul. 31, 2012 in U.S. Appl. No. 12/351,601, 24 pages.;;Notice of Allowance dated Jan. 9, 2014 in U.S. Appl. No. 12/351,601, 9 pages.",ACTIVE
64,TW,A,TW 200848549 A,183-369-446-800-587,2008-12-16,2008,TW 97103864 A,2008-02-01,US 70185407 A,2007-02-02,Apparatus for defining regions of process exclusion and process performance in a process chamber,"Positional relationships are established in a process chamber. A lower electrode is configured with a first surface to support a wafer, and a top electrode has a second surface. A linear drive is mounted on the base and a linkage connected between the drive and the top electrode. Linkage adjustment defines a desired orientation between the surfaces. The linear drive and linkage maintain the desired orientation while the assembly moves the top electrode with the surfaces moving relative to each other. An annular etching region defined between the electrodes enables etching of a wafer edge exclusion region extending along a top and bottom of the wafer. Removable etch defining rings are configured to define unique lengths along each of the top and bottom of the wafer to be etched. Positional relationships of the surfaces enable limiting the etching to those unique lengths of the exclusion region.",LAM RES CORP,BAILEY ANDREW D III;;CHEN JACK;;KIM YUN-SANG;;SEXTON GREG S,,https://lens.org/183-369-446-800-587,Patent of Addition,no,0,1,8,8,0,H01L21/302;;H01L21/67069;;H01L21/67069;;H01J37/32568;;H01J37/32568;;H01L21/02;;H01L21/683;;H01L21/68721;;H01L21/68721,C23F1/00,,0,0,,,,ACTIVE
65,GB,A,GB 2482430 A,193-319-069-060-671,2012-02-01,2012,GB 201114981 A,2011-01-31,GB 201114981 A,2011-01-31,Manufacture of curved low-oil potato chips,"An apparatus for manufacturing curved, low-oil potato chips comprises a microwave oven (4) having a longitudinal cavity (6) forming a microwave chamber and a belt conveyor (24) extending through the microwave chamber. The conveyor comprises a plurality of links, the conveyor surface having a plurality of intersections 84 of adjacent links. At least some of the intersections include a stop surface 90 to prevent a potato slice from sliding in a first longitudinal direction. The stop surface comprises a surface of a first link, the surface being at least partly oriented towards a second longitudinal direction opposite to the first longitudinal direction. In a further embodiment, the conveyor has a continuously undulating surface with a maximum height of the undulations of from 5 to 15 mm and a pitch between adjacent undulations of from 35 to 75 mm.",FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/193-319-069-060-671,Patent Application,no,4,0,3,3,0,A23L5/15;;A23L33/20;;A23L5/15;;A23L19/18;;A23L19/18;;B65G17/083,A23L19/18;;A23L5/10;;B65G17/08,,0,0,,,,INACTIVE
66,GB,B,GB 2481472 B,058-265-774-365-678,2013-01-30,2013,GB 201101625 A,2011-01-31,GB 201101625 A,2011-01-31,Manufacture of low oil potato chip,,FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/058-265-774-365-678,Granted Patent,no,4,0,5,5,0,A23L5/15;;A23L5/15;;A23L5/34;;A23L19/18;;A23L19/18;;A23L33/20;;B65G17/083;;B65G17/40;;B65G17/08,A23L19/12;;A23L5/10;;A23L5/30;;A23L19/18;;A23L33/20;;B65G17/08,,0,0,,,,INACTIVE
67,GB,B,GB 2482251 B,093-657-092-997-223,2012-06-13,2012,GB 201114982 A,2011-01-31,GB 201114982 A,2011-01-31,Manufacture of low oil potato chip,,FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/093-657-092-997-223,Granted Patent,no,4,0,3,3,0,A23L5/15;;A23L5/15;;A23L19/18;;A23L19/18;;A23L33/20;;B65G17/08;;B65G17/08,A23L19/18;;A23L5/10;;B65G17/08,,0,0,,,,INACTIVE
68,CN,A,CN 101305917 A,096-948-603-235-183,2008-11-19,2008,CN 200810074209 A,2008-02-13,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,PINAKI RAY;;GREG MATIAN;;CARRIE ARNDT;;ULRICH KRAFT;;ERIC BAILEY;;MURPHY FREELEN;;DAVID TAYLOR,,https://lens.org/096-948-603-235-183,Patent Application,no,0,8,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/157;;G01N33/66,,0,0,,,,ACTIVE
69,GB,A,GB 2482251 A,150-099-639-088-421,2012-01-25,2012,GB 201114982 A,2011-01-31,GB 201114982 A,2011-01-31,Manufacture of curved low-oil potato chips,"An apparatus for manufacturing curved, low-oil potato chips comprises a microwave oven (4) having a longitudinal cavity (6) forming a microwave chamber and a belt conveyor (24) extending through the microwave chamber. The conveyor has a continuously undulating surface with a maximum height of the undulations of from 5 to 15 mm and a pitch between adjacent undulations of from 35 to 75 mm. The conveyor preferably comprises a plurality of links 50 arranged in a plurality of rows, each row having a leading edge 62 and a trailing edge 64, each of which edges is pivotally connected to a respective adjacent row. Each row has a continuously convex arcuate upper surface for supporting slices of potato. The leading edge and trailing edge of adjacent rows intersect to form an intersection 66 at the intersecting upper surfaces. In a further embodiment, a conveyor surface is formed from a plurality of links wherein some of the intersections between links include a stop surface (90) to prevent potato slices from sliding past the intersection.",FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/150-099-639-088-421,Patent Application,no,4,4,3,3,0,A23L5/15;;A23L5/15;;A23L19/18;;A23L19/18;;A23L33/20;;B65G17/08;;B65G17/08,A23L19/18;;A23L5/10;;B65G17/08,,0,0,,,,INACTIVE
70,GB,B,GB 2482430 B,173-966-485-052-713,2012-06-13,2012,GB 201114981 A,2011-01-31,GB 201114981 A,2011-01-31,Manufacture of low oil potato chip,,FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/173-966-485-052-713,Granted Patent,no,4,0,3,3,0,A23L5/15;;A23L33/20;;A23L5/15;;A23L19/18;;A23L19/18;;B65G17/083,A23L19/18;;A23L5/10;;B65G17/08,,0,0,,,,INACTIVE
71,US,S,US D0690612 S,122-382-309-319-686,2013-10-01,2013,US 201229426845 F,2012-07-11,US 201229426845 F,2012-07-11,Process gas chromatograph,,LAM VINCENT;;BAILEY EDWARD;;WATKINS WILLIS;;HALE SHANE;;MAHONEY PAUL;;GOLDEN GREG;;JONES ART;;ROSEMOUNT ANALYTICAL INC,LAM VINCENT;;BAILEY EDWARD;;WATKINS WILLIS;;HALE SHANE;;MAHONEY PAUL;;GOLDEN GREG;;JONES ART,ROSEMOUNT ANALYTICAL INC (2012-09-24);;ROSEMOUNT INC (2017-12-20),https://lens.org/122-382-309-319-686,Design Right,no,0,6,1,1,0,,,1004;;D10/81,0,0,,,,ACTIVE
72,EP,A1,EP 2670260 A1,112-076-106-270-052,2013-12-11,2013,EP 12701357 A,2012-01-27,GB 201101625 A;;EP 2012051349 W,2011-01-31,MANUFACTURE OF LOW OIL POTATO CHIP,,FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/112-076-106-270-052,Patent Application,yes,0,0,5,5,0,A23L5/15;;A23L5/15;;A23L5/34;;A23L19/18;;A23L19/18;;A23L33/20;;B65G17/083;;B65G17/40;;B65G17/08,A23L19/12;;A23L5/10;;A23L5/30;;A23L19/18;;A23L33/20,,1,0,,,See references of WO 2012104219A1,DISCONTINUED
73,GB,A,GB 2481472 A,007-110-079-069-627,2011-12-28,2011,GB 201101625 A,2011-01-31,GB 201101625 A,2011-01-31,"Manufacture of curved, low-oil potato chips","An apparatus for manufacturing curved, low-oil potato chips comprises a microwave oven (4) having a longitudinal cavity (6) forming a microwave chamber and a belt conveyor (24) extending through the microwave chamber. The conveyor comprises a plurality of links 50 arranged in a plurality of rows, each row having a leading edge 62 and a trailing edge 64, each of which edges is pivotally connected to a respective adjacent row. Each row has a continuously convex arcuate upper surface for supporting slices of potato. The leading edge and trailing edge of adjacent rows intersect to form an intersection 66 at the intersecting upper surfaces. The upper surface between adjacent intersections is entirely convex. A second invention provides a belt conveyor that extends through a microwave chamber having a continuously undulating surface with a maximum height of the undulations of from 5 to 15 mm and a pitch between adjacent undulations of from 35 to 75 mm. In a third invention, a conveyor surface is formed from a plurality of links wherein some of the intersections between links include a stop surface to prevent potato slices from sliding past the intersection.",FRITO LAY TRADING CO GMBH,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/007-110-079-069-627,Patent Application,no,4,1,5,5,0,A23L5/15;;A23L5/15;;A23L5/34;;A23L19/18;;A23L19/18;;A23L33/20;;B65G17/083;;B65G17/40;;B65G17/08,A23L19/12;;A23L5/10;;A23L5/30;;A23L19/18;;A23L33/20;;B65G17/08,,0,0,,,,INACTIVE
74,WO,A1,WO 2012/104219 A1,187-040-687-552-694,2012-08-09,2012,EP 2012051349 W,2012-01-27,GB 201101625 A,2011-01-31,MANUFACTURE OF LOW OIL POTATO CHIP,"An apparatus for manufacturing potato chips from potato slices, the apparatus comprising an elongate microwave oven having a longitudinal cavity forming a microwave chamber, and an elongate longitudinal belt conveyor having a portion extending through the microwave chamber for supporting potato slices conveyed through the microwave chamber, the conveyor comprising a plurality of links arranged in a plurality of rows, each row transversely extending across the width of the endless belt conveyor, each row having a leading edge and a trailing edge, each of which edges is pivotally connected to a respective adjacent row, each row having a continuously convex arcuate upper surface, the leading edge and trailing edge of adjacent rows intersecting to form a transversely extending intersection at the intersecting upper surfaces, and between adjacent intersections the upper surface of each respective row is entirely convex.",FRITO LAY TRADING CO GMBH;;HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,HERBERT OLIVER;;BAILEY RICHARD ANDREW;;WARBURG BARBARA LOUISE;;HILLIARD GREG PAUL;;WORTH PAUL DAVID,,https://lens.org/187-040-687-552-694,Patent Application,yes,6,4,5,5,0,A23L5/15;;A23L5/15;;A23L5/34;;A23L19/18;;A23L19/18;;A23L33/20;;B65G17/083;;B65G17/40;;B65G17/08,A23L19/12;;A23L5/10;;A23L5/30;;A23L19/18;;A23L33/20,,0,0,,,,PENDING
75,AU,B2,AU 2008/200528 B2,005-026-006-625-659,2011-09-15,2011,AU 2008/200528 A,2008-02-05,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time 5 stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively 10 saved glucose readings having time stamps inconsistent with the order index. 05/02/08.document4,17 a:> 0",LIFESCAN INC,ERIC BAILEY;;CARRIE ARNDT;;OLSON MARK H;;ULRICH KRAFT;;GREG MATIAN;;PINAKI RAY;;MURPHY FREELEN;;DAVID TAYLOR,,https://lens.org/005-026-006-625-659,Granted Patent,no,2,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F13/12;;A61B5/00;;G01N21/00,,0,0,,,,INACTIVE
76,AU,A1,AU 2008/200528 A1,012-156-425-970-122,2008-08-28,2008,AU 2008/200528 A,2008-02-05,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,,LIFESCAN INC,BAILEY ERIC;;ARNDT CARRIE;;OLSON MARK H;;KRAFT ULRICH;;MATIAN GREG;;RAY PINAKI;;FREELEN MURPHY;;TAYLOR DAVID,,https://lens.org/012-156-425-970-122,Patent Application,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F13/12;;A61B5/00;;G01N21/00,,0,0,,,,INACTIVE
77,BR,B1,BR PI0800068 B1,015-356-316-010-267,2019-10-22,2019,BR PI0800068 A,2008-02-08,US 70452607 A,2007-02-09,"método para operar um medidor de teste de glicose, método para operar um sistema de gerenciamento de diabetes e medidor de teste de glicose.","método para garantir que a data e hora em um medidor de teste estejam precisas. a presente invenção refere-se a um método de operação de um medidor de teste de glicose. o método pode ser alcançado pelo armazenamento de uma pluralidade de leituras de glicose em uma primeira memória do medidor de teste, cada uma das leituras de glicose possuindo um selo de tempo e um índice de ordem, o selo de tempo compreendendo uma data e uma hora quando a leitura de glicose foi realizada, o índice de ordem indicando uma ordem na qual a pluralidade de leituras de glicose foi salva na primeira memória; determinando se leituras de glicose salvas sucessivamente possuem selos de tempo na ordem cronológica consistentes com o índice de ordem; e indicando que a configuração de data e hora no medidor de teste está incorreta se houver leituras de glicose salvas sucessivamente possuindo selos de tempo inconsistentes com o índice de ordem.",JOHNSON & JOHNSON,CARRIE ARNDT;;DAVID TAYLOR;;ERIC BAILEY;;GREG MATIAN;;MARK H OLSON;;MURPHY FREELEN;;PINAKI RAY;;ULRICH KRAFT,,https://lens.org/015-356-316-010-267,Granted Patent,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G11B27/10,,0,0,,,,INACTIVE
78,CA,C,CA 2619133 C,198-561-559-770-665,2017-10-31,2017,CA 2619133 A,2008-02-06,US 70452607 A,2007-02-09,METHOD OF ENSURING DATE AND TIME ON A TEST METER IS ACCURATE,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/198-561-559-770-665,Granted Patent,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/145;;G01N33/66;;G06F19/00,,0,0,,,,ACTIVE
79,EP,A3,EP 1987766 A3,047-632-972-695-638,2009-06-24,2009,EP 08250484 A,2008-02-08,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.
",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,"LIFESCAN, INC. (2017-04-19)",https://lens.org/047-632-972-695-638,Search Report,yes,2,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F19/00,,1,1,014-595-195-942-667,10.1016/j.diin.2004.07.003,"STEVENS M W: ""Unification of relative time frames for digital forensics"", 20040901, vol. 1, no. 3, 1 September 2004 (2004-09-01), pages 225 - 239, XP004552533",ACTIVE
80,CA,A1,CA 2619133 A1,025-175-593-686-564,2008-08-09,2008,CA 2619133 A,2008-02-06,US 70452607 A,2007-02-09,METHOD OF ENSURING DATE AND TIME ON A TEST METER IS ACCURATE,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the tim e stamp comprising a date and a time when the glucose reading was performed, the ord er index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,TAYLOR DAVID;;OLSON MARK H;;FREELEN MURPHY;;KRAFT ULRICH;;BAILEY ERIC;;MATIAN GREG;;ARNDT CARRIE;;RAY PINAKI,,https://lens.org/025-175-593-686-564,Patent Application,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/145;;G01N33/66;;G06F19/00,,0,0,,,,ACTIVE
81,EP,A2,EP 1987766 A2,144-150-176-738-902,2008-11-05,2008,EP 08250484 A,2008-02-08,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,"LIFESCAN, INC. (2017-04-19)",https://lens.org/144-150-176-738-902,Patent Application,yes,0,12,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F19/00,,0,0,,,,ACTIVE
82,CN,A,CN 102539775 A,063-759-270-113-865,2012-07-04,2012,CN 201110378761 A,2008-02-13,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,PINAKI RAY;;GREG MATIAN;;CARRIE ARNDT;;ULRICH KRAFT;;ERIC BAILEY;;MURPHY FREELEN;;OLSON MARK H;;DAVID TAYLOR,,https://lens.org/063-759-270-113-865,Patent Application,no,7,1,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F19/00;;G01N33/66,,1,0,,,"STEVENS等: ""Unification of relative time frames for digital forensics"", 《DIGITAL INVESTIGATION》",DISCONTINUED
83,TW,B,TW I448274 B,011-868-645-355-796,2014-08-11,2014,TW 97104409 A,2008-02-05,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,,LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/011-868-645-355-796,Granted Patent,no,2,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,,,0,0,,,,INACTIVE
84,BR,A,BR PI0800068 A,045-976-043-586-337,2008-09-23,2008,BR PI0800068 A,2008-02-08,US 70452607 A,2007-02-09,método para garantir que a data e hora em um medidor de teste estejam precisas,"MéTODO PARA GARANTIR QUE A DATA E HORA EM UM MEDIDOR DE TESTE ESTEJAM PRECISAS. A presente invenção refere-se a um método de operação de um medidor de teste de glicose. O método pode ser alcançado pelo armazenamento de uma pluralidade de leituras de glicose em uma primeira memória do medidor de teste, cada uma das leituras de glicose possuindo um selo de tempo e um índice de ordem, o selo de tempo compreendendo uma data e uma hora quando a leitura de glicose foi realizada, o índice de ordem indicando uma ordem na qual a pluralidade de leituras de glicose foi salva na primeira memória; determinando se leituras de glicose salvas sucessivamente possuem selos de tempo na ordem cronológica consistentes com o índice de ordem; e indicando que a configuração de data e hora no medidor de teste está incorreta se houver leituras de glicose salvas sucessivamente possuindo selos de tempo inconsistentes com o índice de ordem.",JOHNSON & JOHNSON,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/045-976-043-586-337,Patent Application,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G11B27/10,,0,0,,,,INACTIVE
85,CN,B,CN 101305917 B,070-759-893-740-084,2012-01-11,2012,CN 200810074209 A,2008-02-13,US 70452607 A,2007-02-09,Method of ensuring accuracy of date and time on a test meter,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,PINAKI RAY;;CARRIE ARNDT;;ERIC BAILEY;;GREG MATIAN;;ULRICH KRAFT;;DAVID TAYLOR;;OLSON MARK H;;MURPHY FREELEN,,https://lens.org/070-759-893-740-084,Granted Patent,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/157;;G01N33/66,,0,0,,,,ACTIVE
86,US,B2,US 9597019 B2,059-454-537-750-803,2017-03-21,2017,US 70452607 A,2007-02-09,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID;;LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,LIFESCAN INC (2007-03-23);;CILAG GMBH INTERNATIONAL (2018-10-01);;LIFESCAN IP HOLDINGS LLC (2018-10-01),https://lens.org/059-454-537-750-803,Granted Patent,yes,21,1,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/00;;A61B5/145;;A61B5/1455;;A61B5/1477;;G01N33/487;;G06F19/00,,18,1,014-595-195-942-667,10.1016/j.diin.2004.07.003,"OneTouch Diabetes Management Software v.2.3.1 User Manual, 2006 LifeScan, Inc. Milpitas, CA 95035 Rev. date Jul. 2006 AW 064-350-01A, pp. 1-173.;;Micael A. Lombardi ""Radio Controlled Clocks"" National Institute of Standards and Technology (NIST) Boulder, Colorado 80305, 2003 NCSL International Workshop and Symposium, pp. 1-18.;;Stevens, M.W.: ""Unification of relative time frames for digital forensics"" , vol. 1, No. 3, Sep. 1, 2004, pp. 225-239, XP004552533.;;European Search Report, European Patent Application No. 08250484.6, dated May 14, 2009, Munich Germany,.;;Japanese Application No. 2008-029667, Notice of Reasons for Rejection, Japanese Patent Office, Sep. 12, 2012, 2 pages.;;Israel Registrar of Patents, Israel Patent Application No. 188783, Notification of Defects dated May 14, 2012, 2 pages.;;Taiwan Application No. 97104409, Search Report, TIPO, Jun. 26, 2013, 1 page.;;Search Report issued in related Chinese Patent Application No. 201110378761.7, dated Jan. 17, 2014, 2 pages.;;First Office Action issued in related Chinese Patent Application No. 2011103787617, dated Jan. 28, 2014, 11 pages.;;Second Office Action issued in related Chinese Patent Application No. 2011103787617, dated Mar. 27, 2015, 10 pages.;;First Office Action issued in related Chinese Patent Application No. 200810074209.7, dated Jul. 14, 2010, 8 pages.;;Second Office Action issued in related Chinese Patent Application No. 2008100742097, dated Jul. 14, 2010, 10 pages.;;Examination Report issued in related European Patent Application No. 08250484.6, dated Jan. 7, 2010, 3 pages.;;Notice of Preliminary Rejection issued in related Korean Patent Application No. 10-2008-0011822, mailed Oct. 22, 2013, 11 pages.;;Notice of Final Rejection issued in related Korean Patent Application No. 10-2008-0011822, mailed Oct. 22, 2013, 6 pages.;;Examination Report issued in related Mexican Patent Application No. MX/a/2008/002033, issued Jul. 15, 2011, 3 pages, with partial English translation.;;Office Action issued in related Russian Patent Application No. 2008104909, issued Jan. 12, 2012, 10 pages.;;Exam Report issued in related Canadian Patent Application No. 2,619,133, issued Jan. 23, 2015, 4 pages.",ACTIVE
87,SG,A1,SG 145625 A1,051-388-853-223-817,2008-09-29,2008,SG 2008009771 A,2008-02-04,US 70452607 A,2007-02-09,METHOD OF ENSURING DATE AND TIME ON A TEST METER IS ACCURATE,"METHOD OF ENSURING DATE AND TIME ON A TEST METER IS ACCURATE A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/051-388-853-223-817,Patent Application,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,,,0,0,,,,PENDING
88,KR,A,KR 20080074786 A,058-590-195-807-67X,2008-08-13,2008,KR 20080011822 A,2008-02-05,US 70452607 A,2007-02-09,METHOD OF ENSURING DATE AND TIME ON A TEST METER IS ACCURATE,"A method for securing a correct time and date in a test meter is provided to improve accuracy of setting date and time without an accurate battery source to reduce an incorrect time and date. A method for securing a correct time and date in a test meter includes the steps of: storing a plurality of blood-sugar levels in a first memory of a test meter(504), wherein the blood-sugar levels have a sequence index for displaying a sequence in which a time stamp having a date and a time and the blood-sugar levels are stored in the first memory; determining whether the sequentially stored blood-sugar levels have the time stamp of a sequence which coincides with the sequence index(508); and if the time stamp of a sequence does not coincide with the sequence index, displaying that the date and time set in the test meter are incorrect.",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/058-590-195-807-67X,Patent Application,no,0,3,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/145,,0,0,,,,ACTIVE
89,TW,A,TW 200845946 A,166-861-591-289-445,2008-12-01,2008,TW 97104409 A,2008-02-05,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a data and a time when the glucose reading was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the data and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/166-861-591-289-445,Patent of Addition,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/145,,0,0,,,,INACTIVE
90,US,A1,US 2008/0194934 A1,084-772-073-111-340,2008-08-14,2008,US 70452607 A,2007-02-09,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,LIFESCAN INC (2007-03-23);;CILAG GMBH INTERNATIONAL (2018-10-01);;LIFESCAN IP HOLDINGS LLC (2018-10-01),https://lens.org/084-772-073-111-340,Patent Application,yes,50,284,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,A61B5/05;;A61B5/00,600/347;;600/365,0,0,,,,ACTIVE
91,ES,T3,ES 2627452 T3,067-832-052-570-535,2017-07-28,2017,ES 08250484 T,2008-02-08,US 70452607 A,2007-02-09,Método para asegurar que la fecha y hora en un medidor de prueba es precisa,"Un método de operar un medidor de prueba de glucosa, el método comprendiendo: almacenar una pluralidad de lecturas de glucosa en una primera memoria de un medidor de prueba, cada una de las lecturas de glucosa teniendo un sello temporal y un índice de orden que es independiente del sello temporal, el sello temporal comprendiendo una fecha y una hora de cuando se realizó la lectura de glucosa, el índice de orden indicando un orden en el que se guardaron la pluralidad de lecturas de glucosa en la primera memoria; determinar si las lecturas de glucosa guardadas sucesivamente tienen sellos temporales en orden cronológico consistente con el índice de orden; y indicar que el ajuste de fecha y hora en el medidor de prueba es incorrecto si hay lecturas de glucosa guardadas sucesivamente que tienen sellos temporales inconsistentes con el índice de orden.",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/067-832-052-570-535,Granted Patent,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F19/00,,0,0,,,,ACTIVE
92,EP,B1,EP 1987766 B1,127-213-695-150-413,2017-05-03,2017,EP 08250484 A,2008-02-08,US 70452607 A,2007-02-09,Method of ensuring date and time on a test meter is accurate,,LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,"LIFESCAN, INC. (2017-04-19)",https://lens.org/127-213-695-150-413,Granted Patent,yes,2,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G06F19/00,,1,0,,,"STEVENS M W: ""Unification of relative time frames for digital forensics"" 20040901, vol. 1, no. 3, 1 September 2004 (2004-09-01), pages 225-239, XP004552533",ACTIVE
93,MX,A,MX 2008002033 A,068-767-343-598-069,2009-02-25,2009,MX 2008002033 A,2008-02-08,US 70452607 A,2007-02-09,METHOD OF ENSURING DATE AND TIME ON A TEST METER IS ACCURATE.,"A method of operating a glucose test meter is provided. The method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading was performed, the order index indicating an order in which the plurality of glucose readings was saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter is incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index.",LIFESCAN INC,TAYLOR DAVID;;KRAFT ULRICH;;RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H,,https://lens.org/068-767-343-598-069,Patent Application,no,0,0,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G01N33/00;;A61B5/157,,0,0,,,,ACTIVE
94,JP,A,JP 2008197102 A,152-230-650-675-436,2008-08-28,2008,JP 2008029667 A,2008-02-08,US 70452607 A,2007-02-09,METHOD OF ENSURING DATE AND TIME ON TEST METER ARE ACCURATE,"<P>PROBLEM TO BE SOLVED: To provide a method of operating a glucose test meter. <P>SOLUTION: This method can be achieved by storing a plurality of glucose readings to a first memory of the test meter, each of the glucose readings having a time stamp and an order index, the time stamp comprising a date and a time when the glucose reading is performed, the order index indicating an order in which the plurality of glucose readings is saved to the first memory; determining whether successively saved glucose readings have time stamps in chronological order consistent with the order index; and indicating that the date and the time setting in the test meter are incorrect if there are successively saved glucose readings having time stamps inconsistent with the order index. <P>COPYRIGHT: (C)2008,JPO&INPIT",LIFESCAN INC,RAY PINAKI;;MATIAN GREG;;ARNDT CARRIE;;KRAFT ULRICH;;BAILEY ERIC;;FREELEN MURPHY;;OLSON MARK H;;TAYLOR DAVID,,https://lens.org/152-230-650-675-436,Patent Application,no,10,5,27,27,0,A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G01N33/48792;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532;;A61B5/14;;G01N33/48792;;A61B5/14551;;A61B5/1477;;A61B2560/0276;;A61B2562/0295;;G16H40/63;;G16H10/60;;G16H40/40;;A61B5/14532,G01N27/26;;A61B5/1455;;A61B5/1486;;G01N27/416,,0,0,,,,ACTIVE
95,US,A1,US 2007/0281949 A1,186-024-863-315-705,2007-12-06,2007,US 80332007 A,2007-05-14,US 80332007 A;;US 80037506 P,2006-05-15,Substituted pyrazolopyrimidines,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,CEPHALON INC (2007-08-09),https://lens.org/186-024-863-315-705,Patent Application,yes,5,24,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,A61K31/519;;A61K31/517;;C07D403/02;;C07D487/02,514/258.1;;514/261.1;;514/262.1;;514/264.11;;514/266.2;;544/262;;544/254;;544/279;;544/284,0,0,,,,INACTIVE
96,US,B2,US 7851468 B2,013-534-339-009-601,2010-12-14,2010,US 80332007 A,2007-05-14,US 80332007 A;;US 80037506 P,2006-05-15,"Substituted pyrazolo[3,4-d]pyrimidines","The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,CEPHALON INC (2007-08-09),https://lens.org/013-534-339-009-601,Granted Patent,yes,11,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,A61K31/541;;A61K31/497;;A61K31/517;;A61K31/519;;A61K31/5355;;C07D279/12;;C07D413/14;;C07D417/14;;C07D487/04;;C07D519/00,514/228.5;;514/234.2;;514/252.16;;514/262.1;;514/261.1;;514/258.1;;514/266.2;;514/264.1;;514/264.11;;544/58.2;;544/61;;544/118;;544/262;;544/254;;544/245;;544/279,3,1,040-077-851-624-417,1120982;;10.1021/jm00236a010,"Wolff, Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part I"", John Wiley & Sons, 1995, pp. 975-977.;;Banker, G.S. et al, ""Modern Pharmaceutics, 3ed."", Marcel Dekker, New York, 1996, p. 596.;;Chu, Ih et al., Journal of Medicinal Chemistry, Synthesis and Biological Evaluation of Xanthine Oxidase Inhibitors, Pyrazolo[3,4-d]pyrimidines and Pyrazolo[3,4-b]pyridines, 1975, 18(2), 161-165.",INACTIVE
97,US,A1,US 2011/0053920 A1,167-251-892-778-195,2011-03-03,2011,US 93952710 A,2010-11-04,US 93952710 A;;US 80332007 A;;US 80037506 P,2006-05-15,SUBSTITUTED BICYCLIC PYRIMIDINES,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,CEPHALON INC (2007-08-09),https://lens.org/167-251-892-778-195,Patent Application,yes,5,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,A61K31/541;;A61K31/517;;A61K31/519;;A61K31/52;;A61K31/5377;;A61P3/04;;A61P3/10;;A61P9/00;;A61P25/00;;A61P29/00;;C07D413/14;;C07D417/14;;C07D471/04;;C07D473/00;;C07D487/04,514/228.5;;544/262;;514/262.1;;544/279;;514/264.1;;544/117;;514/234.5;;514/252.16;;544/58.6;;544/277;;514/263.2,0,0,,,,INACTIVE
98,CA,C,CA 2650227 C,029-971-708-826-874,2015-09-15,2015,CA 2650227 A,2007-05-15,US 80037506 P;;US 80332007 A;;US 2007/0011619 W,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/029-971-708-826-874,Granted Patent,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,INACTIVE
99,ES,T3,ES 2406089 T3,168-296-620-396-922,2013-06-05,2013,ES 07870684 T,2007-05-15,US 80037506 P;;US 80332007 A;;US 2007/0011619 W,2006-05-15,Pirazolpirimidinas sustituidas,"Un compuesto de Fórmula (I): **Fórmula** y formas esteroisoméricas, mezclas de formas esteroisoméricas, formas tautoméricas, profármacos, o formas desales farmacéuticamente aceptables de los mismos, en donde: W es CH o N; el anillo A es R1, R2, R3 y R4 en cada aparición son seleccionados independientemente de H, halo, -OR11, -NO2, -CN, -CF3, -CHF2,alquenilo C2-C4, alquinilo C2-C4, haloalquilo C1-C4, -NR13R14, -NHOR13a, -C(>=O)R15, -C(>=O)OR15, -OC(>=O)R15, -C(>=O) NR13R14, -NR13aC(>=O)R15, -NR13aCO2R15, -OC(>=O)NR13R14, - NR13aC(>=S)R15, -SR15, -S(>=O)R15, -S(>=O)2R15, -S(>=O)2NR13R14, y alquilo C1-C4 sustituido con 0-1 R19.",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/168-296-620-396-922,Granted Patent,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,ACTIVE
100,WO,A3,WO 2008/063232 A3,199-634-838-228-351,2008-07-31,2008,US 2007/0011619 W,2007-05-15,US 80037506 P;;US 80332007 A,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC;;BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/199-634-838-228-351,Search Report,yes,2,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,PENDING
101,CN,B,CN 101448822 B,160-229-136-932-593,2013-11-06,2013,CN 200780017789 A,2007-05-15,US 2007/0011619 W;;US 80037506 P;;US 80332007 A,2006-05-15,Substituted pyrazolopyrimidines,,CEPHALON INC,BACON EDWARD R;;HOSTETLER GREG;;WAGNER JASON C;;BECKNELL NADINE C;;BAILEY THOMAS R;;GINGRICH DIANE E;;LEARN KEITH S;;HUDKINS ROBERT L,,https://lens.org/160-229-136-932-593,Granted Patent,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,A61K31/517;;C07D401/14;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,INACTIVE
102,WO,B1,WO 2008/063232 B1,076-611-363-950-794,2008-09-18,2008,US 2007/0011619 W,2007-05-15,US 80037506 P;;US 80332007 A,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC;;BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/076-611-363-950-794,Patent Application,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,PENDING
103,AU,B2,AU 2007/322382 B2,086-688-277-633-66X,2012-12-20,2012,AU 2007/322382 A,2007-05-15,US 80332007 A;;US 80037506 P;;US 2007/0011619 W,2006-05-15,Substituted pyrazolopyrimidines,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R",CEPHALON INC,LEARN KEITH S;;GINGRICH DIANE E;;BAILEY THOMAS R;;WAGNER JASON C;;BACON EDWARD R;;BECKNELL NADINE C;;HUDKINS ROBERT L;;HOSTETLER GREG,,https://lens.org/086-688-277-633-66X,Granted Patent,no,2,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,INACTIVE
104,HK,A1,HK 1128083 A1,151-779-531-932-892,2009-10-16,2009,HK 09105040 A,2009-06-04,US 2007/0011619 W;;US 80037506 P;;US 80332007 A,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,,CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/151-779-531-932-892,Patent Application,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,A61K/;;C07D/;;A61P/,,0,0,,,,DISCONTINUED
105,US,B2,US 8354414 B2,128-635-396-989-071,2013-01-15,2013,US 93952710 A,2010-11-04,US 93952710 A;;US 80332007 A;;US 80037506 P,2006-05-15,Substituted bicyclic pyrimidines,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC;;BACON EDWARD R;;BAILEY THOMAS;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,BACON EDWARD R;;BAILEY THOMAS;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,CEPHALON INC (2007-08-09),https://lens.org/128-635-396-989-071,Granted Patent,yes,11,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D239/70;;A61K31/517;;A61K31/519;;C07D239/72;;C07D239/78;;C07D239/84;;C07D471/04;;C07D487/04,514/258.1;;514/261.1;;514/264.11;;514/264.1;;514/266.2;;544/253;;544/254;;544/279;;544/284,3,1,040-077-851-624-417,1120982;;10.1021/jm00236a010,"Chu, Ih et al., Journal of Medicinal Chemistry, Synthesis and Biological Evaluation of Xanthine Oxidase Inhibitors, Pyrazolo[3,4-d]pyrimidines and Pyrazolo[3,4-b]pyridines, 1975, 18(2), 161-165.;;Banker, G.S. et al., ""Modern Pharmaceutics, 3ed."", Marcel Dekker, New York, 1996, p. 596.;;Wolff, Manfred E., ""Burger's Medicinal Chemistry, 5ed., Part I"", John Wiley & Sons, pp. 975-977, (1995).",INACTIVE
106,EP,A1,EP 2351751 A1,074-848-149-733-062,2011-08-03,2011,EP 11163915 A,2007-05-15,EP 11163915 A;;US 80037506 P;;US 80332007 A,2006-05-15,Substituted pyrazolopyrimidines,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I):
  
wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/074-848-149-733-062,Patent Application,yes,3,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,33,30,065-180-576-749-671;;001-692-706-535-549;;066-903-590-296-595;;059-744-696-369-706;;108-223-667-468-90X;;016-129-102-313-63X;;006-687-069-314-043;;055-394-111-772-397;;073-891-184-657-744;;011-287-262-575-745;;050-195-349-681-897;;102-330-065-682-98X;;032-736-137-185-556;;000-765-191-351-510;;046-471-648-741-224;;060-899-258-430-599;;004-676-447-741-071;;075-345-426-399-739;;067-923-232-543-60X;;091-391-488-238-284;;140-652-486-343-572;;062-139-125-255-871;;044-173-181-660-106;;008-971-246-454-196;;007-320-893-829-665;;056-794-825-212-497;;019-013-949-592-165;;023-220-379-158-063;;077-295-491-167-117;;040-077-851-624-417,10.1023/a:1006857527588;;10.1007/978-1-4615-5647-3_14;;9609122;;10.1042/bst0210555;;8224471;;10.1093/emboj/17.5.1371;;9482734;;pmc1170485;;0009482734;;10.1038/27208;;9790190;;pmc39697;;10.1073/pnas.93.7.2719;;8610107;;12761548;;10.1038/nature01640;;9468292;;10.1016/s0014-5793(97)01548-2;;11584302;;10.1038/35096019;;10.1074/jbc.m109645200;;11784720;;10604473;;10.1038/45251;;14769920;;10.1073/pnas.0308652100;;pmc357074;;10.1038/nn1119;;14502288;;14749431;;pmc6729809;;10.1523/jneurosci.4582-03.2004;;10.1073/pnas.0307813100;;14704270;;pmc327184;;15676027;;10.1111/j.1365-2443.2005.00827.x;;12794314;;10.1385/jmn:20:2:203;;10.1002/path.1650;;pmc3011821;;15495240;;10499443;;10.1097/00005072-199909000-00011;;9666145;;10.1016/s0006-8993(98)00296-0;;11226152;;pmc140191;;10.1093/emboj/20.1.27;;14642273;;10.1016/s0896-6273(03)00627-5;;10.1038/nrd1415;;15173837;;11837744;;10.1007/s004010100423;;10.1021/bi051635j;;16519508;;10.1073/pnas.190297597;;pmc27150;;10995469;;12732732;;pmc156351;;10.1073/pnas.0937423100;;10.1002/0470052171.ch7;;14744163;;10.4088/jcp.v65n0103;;10.2174/1381612043452668;;15078145;;10.1002/0471220574;;1120982;;10.1021/jm00236a010,"SRIVASTAVA, PANDEY, MOL CELL BIOCHEM., vol. 182, 1998, pages 135 - 141;;COHEN, BIOCHEM SOC TRANS., vol. 21, 1993, pages 555 - 567;;IKEDA ET AL., EMBO, vol. 17, 1998, pages 1371 - 1384;;ZHANG ET AL., NATURE, vol. 395, 1998, pages 698 - 702;;HOSHI ET AL., PNAS, vol. 93, 1996, pages 2719 - 2723;;PHIEL ET AL., NATURE, vol. 423, 2003, pages 435 - 9;;WELSH ET AL., FEBS LETTS, vol. 421, 1997, pages 125 - 130;;DHAVAN, TSAI, NAT REV MOL CELL BIOL, vol. 2, 2001, pages 749 - 759;;PATZKE, TSAI, J BIOL CHEM, vol. 277, 2002, pages 8054 - 8060;;BIBB ET AL., NATURE, vol. 402, 1997, pages 669 - 671;;CHERGUI ET AL., PNAS, vol. 10, 2004, pages 2191 - 2196;;WANG ET AL., NAT NEUROSCI., vol. 6, 2003, pages 1039 - 47;;MORABITO, J NEUROSCI., vol. 24, 2004, pages 865 - 876;;LEE, PNAS, vol. 101, 2004, pages 546 - 551;;UCHIDA ET AL., GENES CELLS, vol. 10, 2005, pages 165 - 179;;HARDY, J MOL NEUROSCI, vol. 20, 2003, pages 203 - 6;;CAIRNS, J PATHOL, vol. 204, 2004, pages 438 - 449;;PEI, J. NEUROPATH. EXP. NEUROL., vol. 58, 1999, pages 1010 - 1019;;PEI, BRAIN RES, vol. 797, 1998, pages 267 - 277;;LUCAS ET AL., EMBO J., vol. 20, 2001, pages 27 - 39;;CRUZ ET AL., NEURON, vol. 40, 2003, pages 471 - 83;;COHEN, GOEDERT, NAT REV DRUG DISCOV, vol. 3, 2004, pages 479 - 487;;AUGUSTINACK, ACTA NEUROPATHOL, vol. 103, 2002, pages 26 - 35;;LI T, HAWKES C, QURESHI HY, KAR S, PAUDEL HK, BIOCHEMISTRY, vol. 45, 2006, pages 3145 - 4154;;BHAT ET AL., PNAS, vol. 97, 2000, pages 11074 - 11079;;REN ET AL., PNAS, vol. 100, 2003, pages 6210 - 6215;;GOULD ET AL., J CLIN PSYCHIATRY, vol. 65, 2004, pages 10 - 21;;WAGMAN ET AL., CURR PHARM DES., vol. 10, 2004, pages 1105 - 1137;;""Prodrugs"", 1992, MARCEL DEKKER;;ELIEL, E. L., WILEN, S.H.: ""Stereochemistry of Organic Compounds"", 1994, WILEY;;JACQUES, J ET AL.: ""Enantiomers, Racemates, and Resolutions"", 1981, WILEY;;GREENE, T.W., WUTS, P.G.M.: ""Protective Groups in Organic Synthesis"", 1991, WILEY & SONS;;CHU, I., LYNCH, B.M.: ""Synthesis and Biological evaluation of Xanthine Oxidase Inhibitors. Pyrazolo[3,4-d]pyrimidines and Pyrazolo[3,4-b]pyridines"", J MED CHEM., vol. 18, 1975, pages 161 - 165",DISCONTINUED
107,MX,A,MX 2008014531 A,189-524-235-366-19X,2009-03-06,2009,MX 2008014531 A,2007-05-15,US 80037506 P;;US 80332007 A;;US 2007/0011619 W,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES.,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC,BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HUDKINS ROBERT L;;BACON EDWARD R;;HOSTETLER GREG;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/189-524-235-366-19X,Patent Application,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,ACTIVE
108,WO,A2,WO 2008/063232 A2,059-613-444-334-558,2008-05-29,2008,US 2007/0011619 W,2007-05-15,US 80037506 P;;US 80332007 A,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,"The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).",CEPHALON INC;;BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/059-613-444-334-558,Patent Application,yes,0,9,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,,,0,0,,,,PENDING
109,EP,A2,EP 2024360 A2,018-715-877-401-496,2009-02-18,2009,EP 07870684 A,2007-05-15,US 2007/0011619 W;;US 80037506 P;;US 80332007 A,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,,CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/018-715-877-401-496,Patent Application,yes,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,ACTIVE
110,CA,A1,CA 2650227 A1,018-596-503-365-567,2008-05-29,2008,CA 2650227 A,2007-05-15,US 80037506 P;;US 80332007 A;;US 2007/0011619 W,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,,CEPHALON INC,BAILEY THOMAS R;;LEARN KEITH S;;HOSTETLER GREG;;HUDKINS ROBERT L;;WAGNER JASON C;;GINGRICH DIANE E;;BECKNELL NADINE C;;BACON EDWARD R,,https://lens.org/018-596-503-365-567,Patent Application,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,INACTIVE
111,AU,A1,AU 2007/322382 A1,162-898-235-395-915,2008-05-29,2008,AU 2007/322382 A,2007-05-15,US 80332007 A;;US 80037506 P;;US 2007/0011619 W,2006-05-15,Substituted pyrazolopyrimidines,,CEPHALON INC,BAILEY THOMAS R;;HOSTETLER GREG;;BECKNELL NADINE C;;WAGNER JASON C;;LEARN KEITH S;;HUDKINS ROBERT L;;GINGRICH DIANE E;;BACON EDWARD R,,https://lens.org/162-898-235-395-915,Patent Application,no,0,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D401/14;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,INACTIVE
112,EP,B1,EP 2024360 B1,190-019-934-213-297,2013-04-03,2013,EP 07870684 A,2007-05-15,US 2007/0011619 W;;US 80037506 P;;US 80332007 A,2006-05-15,SUBSTITUTED PYRAZOLOPYRIMIDINES,,CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;GINGRICH DIANE E;;HOSTETLER GREG;;HUDKINS ROBERT L;;LEARN KEITH S;;WAGNER JASON C,,https://lens.org/190-019-934-213-297,Granted Patent,yes,2,0,26,26,0,C07D401/14;;C07D403/04;;C07D487/04;;A61P15/00;;A61P17/14;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D403/04;;C07D487/04,C07D401/14;;A61K31/517;;A61K31/52;;A61P3/10;;A61P25/16;;A61P25/18;;A61P25/28;;C07D403/04;;C07D473/00;;C07D487/04,,0,0,,,,ACTIVE
113,EP,A1,EP 2459529 A1,087-977-927-629-329,2012-06-06,2012,EP 10730019 A,2010-07-01,US 22260209 P;;US 2010/0040757 W,2009-07-02,SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS,,CEPHALON INC;;CEPHALON FRANCE,BACON EDWARD R;;BAILEY THOMAS;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;YUE CHRISTOPHE;;ZULLI ALLISON L,"CEPHALON, INC. (2013-05-22);;TEVA SANTE (2013-05-22)",https://lens.org/087-977-927-629-329,Patent Application,yes,0,0,5,5,0,C07D207/06;;C07D207/10;;C07D207/27;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D295/108;;C07D295/185;;C07D401/12;;C07D407/12;;C07D409/12;;C07D413/12;;C07D471/04;;C07D487/04;;C07D403/12;;C07D207/08;;C07D211/22;;C07D215/02;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P9/10;;C07D209/44;;C07D217/04;;C07D413/12;;C07D207/06;;C07D409/12;;C07D295/108;;C07D487/04;;C07D215/06;;C07D207/10;;C07D407/12;;C07D401/12;;C07D211/46;;C07D207/27;;C07D471/04;;C07D211/14;;C07D241/08;;C07D211/38;;C07D295/185;;C07D403/12;;C07C217/54;;C07D207/08;;C07D211/22;;C07D215/02,A61K31/496;;C07D207/06;;A61K31/5377;;A61P25/00;;C07D207/10;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D401/12;;C07D403/12;;C07D407/12,,1,1,015-504-557-455-090,15739896,"APELT J ET AL: ""SEARCH FOR HISTAMINE H3 RECEPTOR ANTAGONISTS WITH COMBINED INHIBITORY POTENCY AT N -METHYLTRANSFERASE: ETHER DERIVATIVES"", DIE PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, vol. 60, no. 2, 1 January 2005 (2005-01-01), pages 97 - 106, XP008067213, ISSN: 0031-7144",DISCONTINUED
114,WO,A1,WO 2011/002984 A1,024-111-849-736-432,2011-01-06,2011,US 2010/0040757 W,2010-07-01,US 22260209 P,2009-07-02,SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS,"The present invention provides compounds of formula I: their use as H 3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.",CEPHALON INC;;CEPHALON FRANCE;;BACON EDWARD R;;BAILEY THOMAS;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;YUE CHRISTOPHE;;ZULLI ALLISON L,BACON EDWARD R;;BAILEY THOMAS;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;YUE CHRISTOPHE;;ZULLI ALLISON L,,https://lens.org/024-111-849-736-432,Patent Application,yes,1,2,5,5,0,C07D207/06;;C07D207/10;;C07D207/27;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D295/108;;C07D295/185;;C07D401/12;;C07D407/12;;C07D409/12;;C07D413/12;;C07D471/04;;C07D487/04;;C07D403/12;;C07D207/08;;C07D211/22;;C07D215/02;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P9/10;;C07D209/44;;C07D217/04;;C07D413/12;;C07D207/06;;C07D409/12;;C07D295/108;;C07D487/04;;C07D215/06;;C07D207/10;;C07D407/12;;C07D401/12;;C07D211/46;;C07D207/27;;C07D471/04;;C07D211/14;;C07D241/08;;C07D211/38;;C07D295/185;;C07D403/12;;C07C217/54;;C07D207/08;;C07D211/22;;C07D215/02,C07D207/06;;A61K31/496;;A61K31/5377;;A61P25/00;;C07D207/10;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D401/12;;C07D403/12;;C07D407/12,,21,16,058-820-218-388-262;;022-205-540-150-665;;043-412-491-240-165;;034-920-539-446-387;;049-037-304-790-636;;033-497-186-604-658;;033-810-769-059-776;;029-644-733-710-760;;003-838-254-045-62X;;030-602-367-949-973;;016-112-977-637-521;;012-058-136-528-355;;060-537-779-460-47X;;000-206-887-384-58X;;005-359-431-101-405;;009-550-404-283-996,10.1038/302832a0;;6188956;;10.2174/1568007033482760;;14529362;;10.1016/j.tips.2004.10.003;;15530639;;10.1038/nrd1631;;15665857;;16376822;;10.1016/s1359-6446(05)03625-1;;10.1016/j.pharmthera.2004.05.001;;15251226;;10.1007/s11882-003-0044-3;;12662472;;11890359;;9652190;;10.1016/s0165-6147(98)01201-2;;10.1517/13543784.13.10.1237;;15461554;;10.1124/mi.6.2.5;;16565470;;9353396;;4764313;;10.1016/0006-8993(73)90120-0;;9808693;;8384565;;10.1016/0014-2999(93)90733-x;;3228475;;10.1016/0166-4328(88)90157-x,"BERLIN M ET AL: ""Recent advances in the development of histamine H3 antagonists"", EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, vol. 17, no. 6, 1 June 2007 (2007-06-01), pages 675 - 687, XP002468038, ISSN: 1472-8222;;ARRANG, J. M.; GARBARG, M.; SCHWARTZ, J. C.: ""Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor"", NATURE, vol. 302, no. 5911, 1983, pages 832 - 7, XP001068971, DOI: doi:10.1038/302832a0;;ALGUACIL L. F.; PEREZ-GARCIA C.: ""Histamine H3 Receptor: A potential drug target for the treatment of central nervous systems disorders"", CURRENT DRUG TARGETS-CNS & NEUROLOGICAL DISORDERS, vol. 2, 2003, pages 303 - 131;;PASSANI, M. B.; LIN, J. S.; HANCOCK, A.; CROCHET, S.; BLANDINA, P.: ""The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders"", TRENDS PHARMACOL SCI, vol. 25, 2004, pages 618 - 25, XP004629292, DOI: doi:10.1016/j.tips.2004.10.003;;LEURS, R.; BAKKER, R. A; TIMMCRMAN, H.; DC ESCH, I. J.: ""The histamine H3 receptor: from gene cloning to H3 receptor drugs"", NAT REV DRUG DISCOV, vol. 4, no. 2, 2005, pages 107 - 20, XP055091723, DOI: doi:10.1038/nrd1631;;CELANIRE, S.; WIJTMANS, M.; TALAGA, P.; LEURS, R.; DE ESCH, I. J.: ""Keynote review: histamine H3 receptor antagonists reach out for the clinic"", DRUG DISCOV TODAY, vol. 10, no. 23-24, 2005, pages 1613 - 27, XP005222014, DOI: doi:10.1016/S1359-6446(05)03625-1;;WITKIN, J. M.; NELSON, D. L.: ""Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system"", PHARMACOL THER, vol. 103, 2004, pages 1 - 20, XP002439416, DOI: doi:10.1016/j.pharmthera.2004.05.001;;REPKA-RAMIREZ M. S.: ""New concepts of histamine receptors and actions"", CURRENT ALLERGY AND ASTHMA REPORTS, vol. 3, 2003, pages 227 - 231;;CHAZOT P. L.; HANN V.: ""H3 histamine receptor isoforms: New therapeutic targets in the CNS?"", CURRENT OPINIONS IN INVESTIGATIONAL DRUGS, vol. 2, 2001, pages 1428 - 1431;;LEURS R.; BLANDINA P.; TEDFORD C.; TIMMERMAN H.: ""Therapeutic potential of histamine H3 receptor agonists and antagonists"", TRENDS IN PHARMACOLOGY, vol. 19, 1998, pages 177 - 183;;HANCOCK, A. A.; FOX, G. B.: ""Perspectives on cognitive domains, H3 receptor ligands and neurological disease."", EXPERT OPIN. INVESTIG. DRUGS, vol. 13, 2004, pages 1237 - 1248;;ESBENSHADE, T. A.; OX, G. B.; COWART, M. D.: ""Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders"", MOLECULAR INTERVENTIONS, vol. 6, 2006, pages 77 - 88, XP009078910, DOI: doi:10.1124/mi.6.2.5;;J. CHEM. SOC. PERKIN TRANS., 1987, pages 1465;;EDGAR; SEIDEL, JOURNAL OFPHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 283, 1997, pages 757 - 769;;KTALY, F.S.; JUNE, K.R., PHYSIOL. BEHAV., vol. 28, 1982, pages 841;;LEIBOWITZ, S.F., BRAIN RES., vol. 63, 1973, pages 440;;LIGNEAU X.; LIN, J-S.; VANNI-MERCIER G.; JOUVET M.; MUIR J.L.; GANELLIN C.R.; STARK H.; ELZ S.; SCHUNACK W.; SCHWARTZ, J-C., JPHARMCOL. EXP. THER., vol. 287, 1998, pages 658 - 66;;CLAPHAM, J.; KILPATRICK G.J., EUR..I. PHARMACOL., vol. 232, 1993, pages 99 - 103;;ENNACEUR, A.; DELACOUR, J., BEHAV BRAIN RES, vol. 31, 1988, pages 47 - 59;;THOR, D.; HOLLOWAY, W., J COMP PHYSIOLOG PSYCHCOL, vol. 96, 1982, pages 1000 - 1006;;See also references of EP 2459529A1",PENDING
115,US,A1,US 2014/0296212 A1,196-256-047-602-541,2014-10-02,2014,US 201414177046 A,2014-02-10,US 201414177046 A;;US 201113334311 A;;US 2010/0040757 W;;US 22260209 P,2009-07-02,SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS,"The present invention provides compounds of formula I: their use as H 3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.",BACON EDWARD R;;BAILEY THOMAS R;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;ZULLI ALLISON L;;LESUR BRIGITTE;;SUNDAR BABU G;;YUE CHRISTOPHE;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;ZULLI ALLISON L;;LESUR BRIGITTE;;SUNDAR BABU G;;YUE CHRISTOPHE,,https://lens.org/196-256-047-602-541,Patent Application,yes,0,0,5,5,0,C07D207/06;;C07D207/10;;C07D207/27;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D295/108;;C07D295/185;;C07D401/12;;C07D407/12;;C07D409/12;;C07D413/12;;C07D471/04;;C07D487/04;;C07D403/12;;C07D207/08;;C07D211/22;;C07D215/02;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P9/10;;C07D209/44;;C07D217/04;;C07D413/12;;C07D207/06;;C07D409/12;;C07D295/108;;C07D487/04;;C07D215/06;;C07D207/10;;C07D407/12;;C07D401/12;;C07D211/46;;C07D207/27;;C07D471/04;;C07D211/14;;C07D241/08;;C07D211/38;;C07D295/185;;C07D403/12;;C07C217/54;;C07D207/08;;C07D211/22;;C07D215/02,C07D403/12;;C07C217/54;;C07D207/08;;C07D209/44;;C07D211/22;;C07D215/02;;C07D217/04,514/217.01;;514/235.5;;514/316;;514/326;;514/307;;514/323;;514/314;;514/254.01;;514/227.8,0,0,,,,DISCONTINUED
116,US,A1,US 2012/0238551 A1,137-662-931-108-855,2012-09-20,2012,US 201113334311 A,2011-12-22,US 201113334311 A;;US 2010/0040757 W;;US 22260209 P,2009-07-02,Substituted Phenoxypropylcycloamine Derivatives as Histamine-3 (H3) Receptor Ligands,"The present invention provides compounds of formula I: their use as H 3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.",BACON EDWARD R;;BAILEY THOMAS R;;CHATTERJEE SANKAR;;DUNN DEREK D;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;ZULLI ALLIZON L;;YUE CHRISTOPHE;;CEPHALON FRANCE;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;CHATTERJEE SANKAR;;DUNN DEREK D;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;ZULLI ALLIZON L;;YUE CHRISTOPHE,CEPHALON INC (2010-07-30);;TEVA SANTE (2012-12-31);;CEPHALON FRANCE (2010-08-23),https://lens.org/137-662-931-108-855,Patent Application,yes,4,1,5,5,0,C07D207/06;;C07D207/10;;C07D207/27;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D295/108;;C07D295/185;;C07D401/12;;C07D407/12;;C07D409/12;;C07D413/12;;C07D471/04;;C07D487/04;;C07D403/12;;C07D207/08;;C07D211/22;;C07D215/02;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P9/10;;C07D209/44;;C07D217/04;;C07D413/12;;C07D207/06;;C07D409/12;;C07D295/108;;C07D487/04;;C07D215/06;;C07D207/10;;C07D407/12;;C07D401/12;;C07D211/46;;C07D207/27;;C07D471/04;;C07D211/14;;C07D241/08;;C07D211/38;;C07D295/185;;C07D403/12;;C07C217/54;;C07D207/08;;C07D211/22;;C07D215/02,A61K31/5377;;A61K31/4025;;A61K31/454;;A61K31/4545;;A61K31/4725;;A61K31/496;;A61K31/506;;A61K31/541;;A61K31/55;;A61P3/04;;A61P9/10;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;C07D401/12;;C07D403/12;;C07D413/12;;C07D487/04,514/213.01;;544/141;;514/235.5;;544/372;;514/254.01;;544/130;;546/188;;514/316;;548/518;;514/422;;546/146;;514/307;;546/200;;514/323;;546/208;;514/326;;544/360;;514/253.01;;544/58.5;;514/227.8;;544/58.6;;544/117;;514/233.2;;540/593;;544/295;;514/252.19,2,1,015-504-557-455-090,15739896,"Apelt, J., et al. Search for Histamine H3 receptor antagonists with combined inhibitory potency at N-methyltransferase: ether derivatives. Pharmazie Vol. 60 Pages 97-106. Published 2005.;;Apelt, J. et al. Pharmazie, Vol. 60, pages 97-016. Published 2005.",INACTIVE
117,US,B2,US 8648067 B2,146-163-119-896-803,2014-02-11,2014,US 201113334311 A,2011-12-22,US 201113334311 A;;US 2010/0040757 W;;US 22260209 P,2009-07-02,Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands,"The present invention provides compounds of formula I: their use as H 3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.",BACON EDWARD R;;BAILEY THOMAS R;;CHATTERJEE SANKAR;;DUNN DEREK D;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;ZULLI ALLISON L;;YUE CHRISTOPHE;;CEPHALON INC;;TEVA SANTE,BACON EDWARD R;;BAILEY THOMAS R;;CHATTERJEE SANKAR;;DUNN DEREK D;;HOSTETLER GREG A;;HUDKINS ROBERT L;;LESUR BRIGITTE;;SUNDAR BABU G;;ZULLI ALLISON L;;YUE CHRISTOPHE,CEPHALON INC (2010-07-30);;TEVA SANTE (2012-12-31);;CEPHALON FRANCE (2010-08-23),https://lens.org/146-163-119-896-803,Granted Patent,yes,7,1,5,5,0,C07D207/06;;C07D207/10;;C07D207/27;;C07D209/44;;C07D211/14;;C07D211/38;;C07D211/46;;C07D215/06;;C07D217/04;;C07D241/08;;C07D295/108;;C07D295/185;;C07D401/12;;C07D407/12;;C07D409/12;;C07D413/12;;C07D471/04;;C07D487/04;;C07D403/12;;C07D207/08;;C07D211/22;;C07D215/02;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/04;;A61P9/10;;C07D209/44;;C07D217/04;;C07D413/12;;C07D207/06;;C07D409/12;;C07D295/108;;C07D487/04;;C07D215/06;;C07D207/10;;C07D407/12;;C07D401/12;;C07D211/46;;C07D207/27;;C07D471/04;;C07D211/14;;C07D241/08;;C07D211/38;;C07D295/185;;C07D403/12;;C07C217/54;;C07D207/08;;C07D211/22;;C07D215/02,A61K31/55;;A01N43/40;;A61K31/445;;A61K31/45;;A61K31/497;;A61K31/535;;A61K31/54;;A61K31/545;;C07D211/00;;C07D217/00;;C07D223/18;;C07D279/10;;C07D295/00;;C07D401/00;;C07D403/00;;C07D405/00;;C07D413/00,514/213;;514/227.8;;514/233.2;;514/235.5;;514/253.01;;514/254.01;;514/316;;514/323;;514/326;;540/593;;544/58.6;;544/117;;544/130;;544/141;;544/295;;544/360;;546/146;;546/188;;546/200;;546/208;;548/518,4,4,015-504-557-455-090;;015-504-557-455-090;;008-431-382-292-366;;026-232-907-470-112,15739896;;15739896;;20144064;;10.1517/13543776.17.6.675;;12113835;;10.1016/s0960-894x(02)00309-8,"Apelt, J., et al. Search for Histamine H3 receptor antagonists with combined inhibitory potency at N-methyltransferase: ether derivatives. Pharmazie vol. 60 pp. 97-106. Published 2005.;;Apelt, J. et al. Pharmazie, vol. 60, pp. 97-016. Published 2005.;;Berlin, M. et al., ""Recent advances in the development of histamine H-3 antagonists"", Expert Opin. Ther. Targets, Ashley Publications, 2007, 17(6), pp. 675-687.;;Faghih, R. et al, ""Structure-Activity Relationships of Non-imidazole H3 Receptor Ligands, Part 1"", Biorg. Med. Chem. Lett. 12, 2002, pp. 2031-2034.",INACTIVE
118,WO,A2,WO 2011/087712 A2,087-475-744-720-779,2011-07-21,2011,US 2010/0060937 W,2010-12-17,US 28909009 P,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS,"This application relates to tricyclic compounds of Formula (I), including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula (I) and uses therefore.",CEPHALON INC;;BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/087-475-744-720-779,Patent Application,yes,3,4,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,41,19,061-702-817-596-929;;116-334-179-476-312;;088-697-732-963-167;;001-693-376-123-991;;110-436-078-694-563;;073-948-078-291-421;;054-295-191-611-832;;086-389-324-219-905;;012-494-151-394-886;;032-177-709-050-924;;013-653-096-922-114;;018-625-829-773-341;;027-729-722-591-620;;006-772-884-929-585;;001-650-562-683-124;;008-294-617-927-728;;009-282-384-928-022;;005-296-667-964-439;;011-648-731-659-388,7680751;;9585121;;10.1016/s0024-3205(98)00092-7;;10.1016/s0040-4039(01)01191-1;;10.1021/jm00129a031;;2549247;;18691131;;10.2174/156802608785161420;;10.1159/000054876;;11287786;;10.1002/(sici)1096-8628(20000403)96:2<217::aid-ajmg17>3.3.co;2-s;;10893499;;10.1002/(sici)1096-8628(20000403)96:2<217::aid-ajmg17>3.0.co;2-0;;17320917;;10.1016/j.neuropharm.2007.01.007;;10.1016/j.pbb.2005.05.005;;15964617;;16005519;;10.1016/j.pharmthera.2005.05.001;;pmc5084247;;10.1016/j.nurt.2008.05.008;;18625457;;18220076;;10.1093/sleep/31.1.34;;pmc2225549;;17599826;;10.1016/j.ejphar.2007.05.020;;pmc1565929;;10.1038/sj.bjp.0702445;;10323584;;19756773;;10.1007/s00520-009-0739-7;;12067777;;10.1016/s0885-3924(02)00391-3;;298353;;10.1016/0165-1781(79)90007-6;;16366767;;10.1037/1064-1297.13.4.367;;10.1016/s0021-9258(19)50171-5;;1349606,"MOL. PHARMACOL, vol. 43, 1993, pages 320 - 327;;J NEUROCHEM, vol. 66, 1996, pages 47 - 56;;CURR DRUQ TARQETS CNS NEUROL DISORD, vol. 3, 2004, pages 59 - 79;;LIFE SCIENCES, vol. 62, 1998, pages 1473 - 1477;;DRUQ DISCOVERY TODAV, vol. 11, 2006, pages 283 - 299;;T. HIGUCHI; W. STELLA: ""Prodrugs as Novel Delivery Systems"", vol. 14, ACS SYMPOSIUM SERIES;;""Bioreversible Carriers in Druq Desiqn"", 1987, PERGAMON PRESS;;TETRAHEDRON LETTERS, vol. 42, 2001, pages 6499 - 6502;;SYNTHESIS, vol. 4, 2005, pages 547 - 550;;J. MED. CHEM., vol. 48, 2005, pages 1781 - 1795;;SYNTH. COMM., vol. 23, 1993, pages 65 - 72;;J. MED. CHEM., vol. 32, 1989, pages 2221 - 2226;;""Compendium of Orqanic Synthetic Methods"", vol. I-VI, WILEY-INTERSCIENCE;;""Protective Groups in Orqanic Svnthesis"", 1999, JOHN WILEY & SONS;;""Reminqton's Pharmaceutical Sciences"", 1995, MACK PUBLISHING COMPANY;;CURRENT DRUQ TARQETS -CNS & NEUROLOQICAL DISORDERS, vol. 3, 2004, pages 59 - 79;;CURR TOP MED CHEM, vol. 8, 2008, pages 1035 - 48;;CURR OPIN DRUO DISCOV DEVEL, vol. 11, 2008, pages 642 - 54;;NEUROPSYCHOBIOLOGY, vol. 43, 2001, pages 113 - 116;;AM. J. MED. GENET., vol. 96, 2000, pages 217 - 221;;NEUROPHARMACOLOGY, vol. 52, 2007, pages 1274 - 83;;PHARMACOLOGY. BIOCHEMISTRY, AND BEHAVIOR, vol. 81, 2005, pages 673 - 82;;PHARMACOL. THER., vol. 108, 2005, pages 320 - 333;;NEUROTHERAPEUTICS, vol. 5, 2008, pages 458 - 469;;EXPERT OPIN. INVEST. DRUAS., vol. 11, 2002, pages 457 - 467;;SLEEP, vol. 31, 2008, pages 34 - 44;;EUROPEAN J. PHARMACOL., vol. 569, 2007, pages 59 - 63;;J. PSVCHOPHARMACOL., vol. 11, 1997, pages A64;;BR. J. PHARMACOL., vol. 126, 1999, pages 1537 - 1542;;INT. J. OBES., vol. 27, no. 1, 2003, pages 1 - 094;;34TH ANNU. MEET SOC. NEUROSCI;;DRUO DISC TODAV, vol. 11, 2006, pages 283 - 299;;PHARMACOLOQV & THERAPEUTICS, vol. 117, 2008, pages 207 - 231;;""Support Care Cancer"", 11 September 2009, article ""Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial"";;J. PAIN SYMPTOM MANAGE., vol. 23, 2002, pages 526 - 532;;J. PALLIATIVE CARE, vol. 6, 2003, pages 251 - 255;;J. PAIN SYMPTOM MANAQE., vol. 25, 2003, pages 587 - 582;;PSYCHIATRY RES, vol. 1, 1979, pages 255 - 264;;NEUROPSVCHOBIOLOQV, vol. 34, 1996, pages 136 - 145;;EXP. CLIN. PSVCHOPHARMACOL, vol. 13, 2005, pages 367 - 375;;J BIO CHEM., vol. 267, no. 14, 1992, pages 9844 - 51",PENDING
119,WO,A3,WO 2011/087712 A3,059-770-764-145-691,2011-09-29,2011,US 2010/0060937 W,2010-12-17,US 28909009 P,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS,"This application relates to tricyclic compounds of Formula (I), including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula (I) and uses therefore.",CEPHALON INC;;BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/059-770-764-145-691,Search Report,yes,3,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,0,0,,,,PENDING
120,HK,A1,HK 1174919 A1,092-201-348-198-811,2013-06-21,2013,HK 13102198 A,2013-02-21,US 2010/0060937 W;;US 28909009 P,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS,,CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/092-201-348-198-811,Patent Application,no,0,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D/;;A61K/;;A61P/,,0,0,,,,DISCONTINUED
121,EP,A2,EP 2516445 A2,176-234-612-583-951,2012-10-31,2012,EP 10799203 A,2010-12-17,US 28909009 P;;US 2010/0060937 W,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS,,CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/176-234-612-583-951,Patent Application,yes,0,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,1,0,,,See references of WO 2011087712A2,ACTIVE
122,MX,A,MX 2012007253 A,113-867-285-442-290,2012-07-17,2012,MX 2012007253 A,2010-12-17,US 28909009 P;;US 2010/0060937 W,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS.,"This application relates to tricyclic compounds of Formula (I), including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula (I) and uses therefore.",CEPHALON INC,BACON EDWARD R;;SALVINO JOSEPH M;;MORTON GEORGE C;;TRIPATHY RABINDRANATH;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;ROSSE GERARD C;;SUNDAR BABU G,,https://lens.org/113-867-285-442-290,Patent Application,no,0,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,0,0,,,,ACTIVE
123,US,A1,US 2012/0295882 A1,193-194-143-313-926,2012-11-22,2012,US 201213529378 A,2012-06-21,US 201213529378 A;;US 2010/0060937 W;;US 28909009 P,2009-12-22,Tricyclic Derivatives and Their Pharmaceutical Use and Compositions,"This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.",BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,CEPHALON INC (2011-01-04),https://lens.org/193-194-143-313-926,Patent Application,yes,0,1,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,A61K31/4355;;A61K31/438;;A61K31/444;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/497;;A61K31/506;;A61K31/5377;;A61P3/04;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;C07D491/048;;C07D491/20;;C07D491/22;;C07D495/20;;C07D513/04,514/210.16;;546/89;;514/291;;546/18;;514/278;;544/316;;514/274;;544/405;;514/255.05;;544/126;;514/232.8;;546/64;;544/361;;514/253.03,1,1,055-862-172-083-303,10.1021/jo9916176;;10789456,"Thomas Engler et al, lewis Acid- Directed Cyclocondensation of Piperidone Enol Ethers.... 2000, pages 2444-2457.",INACTIVE
124,ES,T3,ES 2539382 T3,077-505-621-388-878,2015-06-30,2015,ES 10799203 T,2010-12-17,US 28909009 P;;US 2010/0060937 W,2009-12-22,Derivados tricíclicos y su uso farmacéutico y composiciones,"Un compuesto de fórmula II**Fórmula** o una sal del mismo, en la que: A es -(CR9R10)n- y n es 1, 2 ó 3 y R9 y R10 en cada aparición están seleccionados independientemente de H o alquilo (C1-C6) sin sustituir o haloalquilo (C1-C6); R1 en cada aparición está seleccionado independientemente de H, halógeno, CN, NO2, NR11R12, COR13, CO2R13, alquilo (C1-C6), haloalquilo (C1-C6), alquil (C1-C6)-alcoxi (C1-C6), alquil (C1-C6)-haloalcoxi (C1-C6), cicloalquilo (C3-C10), a l quil (C1-C6)-cicloalquilo (C3-C10), arilo (C6-C10), alquil (C1-C6)-arilo (C6-C10), heterocicloalquilo (C2-C9), alquil (C1-C6)-heterocicloalquilo (C2-C9), heteroarilo (C5-C9) y alquil (C1-C6)- heteroarilo (C5-C9), y W es 0, 1, 2 ó 3, en el que cualquiera de los anteriores, excepto H, halógeno, CN y NO2, está opcionalmente sustituido con uno o más sustituyentes; R2 está seleccionado de H, alquilo (C1-C6), haloalquilo (C1-C6), alquil (C1-C6)-alcoxi (C1-C6), CO-alquilo (C1- C6), CO2-alquilo (C1-C6), CO-arilo (C6-C10), CO2-arilo (C6-C10), arilo (C6-C10), alquil (C1-C6)-arilo (C6-C10), cicloalquilo (C3-C10), CO-cicloalquilo (C3-C10), CO2-cicloalquilo (C3-C10), alquil (C1-C6)-cicloalquilo (C3-C10), CO-alquil (C1-C6)-cicloalquilo (C3-C10), CO2-alquil (C1-C6)-cicloalquilo (C3-C10), heterocicloalquilo (C2-C9), alquil (C1-C6)-heterocicloalquilo (C2-C9), CO-alquil (C1-C6)-heterocicloalquilo (C2-C9), CO2-alquil (C1-C6)- heterocicloalquilo (C2-C9), heteroarilo (C5-C9), CO-heteroarilo (C5-C9), CO2-heteroarilo (C5-C9), alquil (C1- C6)-heteroarilo (C5-C9), CO-alquil (C1-C6)-heteroarilo (C5-C9) y CO2-alquil (C1-C6)-heteroarilo (C5-C9), en el que cualquiera de los anteriores, excepto H, está opcionalmente sustituido con uno o más sustituyentes; R3 y R4 están seleccionados cada uno independientemente de H, alquilo (C1-C6), haloalquilo (C1-C6), alcoxi (C1-C6), amino (C1-C6)-alquilo, haloalcoxi (C1-C6), alquil (C1-C6)-alcoxi (C1-C6), alquil (C1-C6)-NR13CO-alquilo (C1-C6), alquil (C1-C6)-CON(R13)2, arilo (C6-C10), ariloxi (C6-C10), alquil (C1-C6)-arilo (C6-C10), alquil (C1-C6)- ariloxi (C6-C10), cicloalquilo (C3-C10), cicloalquiloxi (C3-C6), alquil (C1-C6)-cicloalquilo (C3-C10), alquil (C1-C6)- cicloalquiloxi (C3-C10), heteroarilo (C5-C9), heteroariloxi (C5-C9), heterocicloalquilo (C2-C9), heterocicloalquiloxi (C2-C9), alquil (C1-C6)-heterocicloalquilo (C2-C9), alquil (C1-C6)-heterocicloalquiloxi (C2- C9), alquil (C1-C6)-heteroarilo (C5-C9) y alquil (C1-C6)-heteroariloxi (C5-C9), en el que cualquiera de los anteriores, excepto H, está opcionalmente sustituido con uno o más sustituyentes; o R3 y R4 se toman conjuntamente para formar un anillo espirocíclico de cicloalquilo (C4-C10) o heterocicloalquilo (C4-C9), en el que cualquiera de los anteriores está opcionalmente sustituido con uno o más sustituyentes seleccionados de alquilo (C1-C6), haloalquilo (C1-C6), hidroxialquilo (C1-C6), COR11, CO2R11, CONR11R13, halógeno, alcoxi (C1-C6), haloalcoxi (C1-C6), OR13 y oxo; o R2 y uno de R3 o R4 se toman conjuntamente para formar un anillo de heterocicloalquilo (C3-C9) opcionalmente sustituido y el otro de R3 o R4 está seleccionado de H, alquilo (C1-C6) e hidroxialquilo (C1- C6); ""----"" es un enlace o está ausente; R5 y R6 están seleccionados cada uno independientemente de H, alquilo (C1-C6), hidroxialquilo (C1-C6) y OH a condición de que ""----"" esté ausente; R7 y R8 están seleccionados cada uno independientemente de H, alquilo (C1-C6) o haloalquilo (C1-C6); o R7 y R8 se toman conjuntamente para formar un anillo de cicloalquilo (C4-C10) o un anillo espirocíclico de heterocicloalquilo (C4-C9), en el que cualquiera de los anteriores está opcionalmente sustituido con uno o más sustituyentes; R11 y R12 en cada aparición están seleccionados independientemente de H, alquilo (C1-C6), alcoxi (C1-C6), alquil (C1-C6)-alcoxi (C1-C6) e hidroxialquilo (C1-C6); R13 en cada aparición está seleccionado independientemente de H y alquilo (C1-C6); Q está ausente, es -O- o -NR13-; Z es 1 ó 2; y Y está seleccionado de cicloalquilo (C3-C10), alquil (C1-C6)-cicloalquilo (C3-C10), heterocicloalquilo (C2-C9), alquil (C1-C6)-heterocicloalquilo (C2-C9), arilo (C6-C10), alquil (C1-C6)-arilo (C6-C10), heteroarilo (C5-C9) y alquil (C1-C6)-heteroarilo (C5-C9), en el que cualquiera de los anteriores está opcionalmente sustituido con uno o más sustituyentes; o Y es NR14R15 en la que R14 y R15 se toman conjuntamente para formar un anillo de heterocicloalquilo (C2- C9) opcionalmente sustituido con uno o más sustituyentes.",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/077-505-621-388-878,Granted Patent,no,0,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,0,0,,,,ACTIVE
125,CA,A1,CA 2785058 A1,155-414-436-872-346,2011-07-21,2011,CA 2785058 A,2010-12-17,US 28909009 P;;US 2010/0060937 W,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS,"This application relates to tricyclic compounds of Formula (I), including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula (I) and uses therefore.",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/155-414-436-872-346,Patent Application,no,0,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,0,0,,,,DISCONTINUED
126,EP,B1,EP 2516445 B1,135-077-610-434-983,2015-03-11,2015,EP 10799203 A,2010-12-17,US 28909009 P;;US 2010/0060937 W,2009-12-22,TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS,,CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,,https://lens.org/135-077-610-434-983,Granted Patent,yes,3,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,C07D491/048;;A61K31/4355;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/36;;C07D491/153;;C07D491/20;;C07D513/04,,0,0,,,,ACTIVE
127,US,B2,US 8765779 B2,169-612-715-784-440,2014-07-01,2014,US 201213529378 A,2012-06-21,US 201213529378 A;;US 2010/0060937 W;;US 28909009 P,2009-12-22,Tricyclic derivatives and their pharmaceutical use and compositions,"This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.",BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;DUNN DEREK D;;HOSTETLER GREG A;;MCHUGH ROBERT J;;MORTON GEORGE C;;ROSSE GERARD C;;SALVINO JOSEPH M;;SUNDAR BABU G;;TRIPATHY RABINDRANATH,CEPHALON INC (2011-01-04),https://lens.org/169-612-715-784-440,Granted Patent,yes,5,0,12,12,0,A61P1/04;;A61P1/14;;A61P3/04;;A61P7/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D491/153;;C07D491/153;;C07D491/048;;C07D491/048;;C07D491/20;;C07D491/20;;C07D513/04;;C07D513/04,A61K31/4355;;C07D491/048,514/291;;546/89,34,34,055-862-172-083-303;;006-772-884-929-585;;005-296-667-964-439;;073-948-078-291-421;;046-452-424-333-455;;011-648-731-659-388;;055-862-172-083-303;;007-510-006-832-559;;027-729-722-591-620;;110-436-078-694-563;;189-736-284-852-092;;076-434-772-060-595;;126-987-596-095-765;;001-693-376-123-991;;107-778-299-192-534;;003-366-077-609-208;;133-606-455-023-727;;056-352-364-630-435;;039-879-759-968-03X;;032-177-709-050-924;;061-702-817-596-929;;018-625-829-773-341;;088-697-732-963-167;;001-650-562-683-124;;008-294-617-927-728;;012-494-151-394-886;;121-591-188-393-672;;013-653-096-922-114;;054-295-191-611-832;;086-389-324-219-905;;076-664-219-163-680;;015-297-645-449-660;;116-334-179-476-312;;009-282-384-928-022,10.1021/jo9916176;;10789456;;pmc1565929;;10.1038/sj.bjp.0702445;;10323584;;16366767;;10.1037/1064-1297.13.4.367;;10.1159/000054876;;11287786;;8916071;;10.1159/000119305;;10.1016/s0021-9258(19)50171-5;;1349606;;10.1021/jo9916176;;10789456;;10.1016/s0040-4039(97)01391-9;;17599826;;10.1016/j.ejphar.2007.05.020;;18691131;;10.2174/156802608785161420;;10.1016/j.pharmthera.2007.08.006;;18068807;;10.1016/j.drudis.2006.04.002;;15771424;;10.1021/jm049615n;;10.1021/jm00129a031;;2549247;;18729016;;10.1055/s-2005-861791;;10.1046/j.1471-4159.1996.66010047.x;;8522988;;10.1002/adsc.200404299;;10.1080/00397919308020402;;16005519;;10.1016/j.pharmthera.2005.05.001;;7680751;;18220076;;10.1093/sleep/31.1.34;;pmc2225549;;10.1016/s0040-4039(01)01191-1;;19756773;;10.1007/s00520-009-0739-7;;12067777;;10.1016/s0885-3924(02)00391-3;;10.1016/j.pbb.2005.05.005;;15964617;;10.1016/s0885-3924(03)00143-x;;12782438;;pmc5084247;;10.1016/j.nurt.2008.05.008;;18625457;;10.1002/(sici)1096-8628(20000403)96:2<217::aid-ajmg17>3.3.co;2-s;;10893499;;10.1002/(sici)1096-8628(20000403)96:2<217::aid-ajmg17>3.0.co;2-0;;17320917;;10.1016/j.neuropharm.2007.01.007;;10.1517/13543784.11.4.457;;11922855;;10.2174/1568007043482561;;14965245;;9585121;;10.1016/s0024-3205(98)00092-7;;298353;;10.1016/0165-1781(79)90007-6,"Thomas Engler et al, lewis Acid- Directed Cyclocondensation of Piperidone Enol Ethers . . . 2000, pp. 2444-2457.;;Bentley et al., ""Investigation of stretching behavior induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats,"" British Journal of Pharmacology (1999), vol. 126, pp. 1537-1542.;;Cain et al., ""Novelty Seeking and Drug Use: Contribution of an Animal Model,"" Experimental and Clinical Psychopharmacology (2005), vol. 13, pp. 367-375.;;Chiu et al., ""Serotonin 6 Receptor Polymorphism in Schizophrenia: Frequency, Age at Onset and Cognitive Function"", Neuropsychobiology (2001), vol. 43, pp. 113-116.;;Dellu et al., ""Novelty-Seeking in Rats-Biobehavioral Characteristics and Possible Relationship with the Sensation-Seeking Trait in Man,"" Neuropsychobiology (1996), vol. 34, pp. 136-145.;;Duzic et al., ""Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-Binding Protein-Coupled Receptors"", J. Biological Chemistry (1992), vol. 267, pp. 9844-9851.;;Engler et al., ""Lewis Acid-Directed Cyclocondensation of Piperidone Enol Ethers with 2-Methoxy-4-(N-phenylsulfonyl)-1,4,-benzoquinoneimine: A New Regioselective Synthesis of Oxygenated Carbolines"", J. Org. Chem. (2000), vol. 65, pp. 2444-2457.;;Engler et al., ""Lewis Acid-Directed Reactions of Benzoquinone Mono-/Bis-imines: Application to Syntheses of Substituted beta- and gamma-Tetrahydrocarbolines"", Tetrahedron Letters (1997), vol. 38, pp. 6135-6138.;;Finn et al., ""The effects of pharmacological blockade of the 5-HT6 receptor on formalin-evoked nociceptive behavior, locomotor activity and hypothalamo-pituitary-adrenal axis activity in rats"", European J. Pharmacology (2007), vol. 569, pp. 59-63.;;Geldenhuys et al., ""Serotonin 5-HT6 Receptor Antagonists for the Treatment of Alzheimer's Disease,"" Curr. Topics in Med. Chem. (2008), vol. 8, pp. 1035-1048.;;Heal et al., ""Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders,"" Pharmacology & Therapeutics (2008), vol. 117, pp. 207-231.;;Holenz et al., ""Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents,"" Drug Discovery (2006), vol. 11, pp. 283-299.;;Holenz et al., ""Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT6 Receptor Ligands,"" J. Med. Chem. . . . (2005), vol. 48, pp. 1781-1795.;;Hutchison et al., ""Benzofuro[2,3-c]pyridin-6-ols: Synthesis, Affinity for Opioid-Receptor Subtypes, and Antinociceptive Activity,"" J. Med. Chem. (1989), vol. 32, pp. 2221-2226.;;Johnson et al., ""5-HT6 receptor antagonists: Prospects for the treatment of cognitive disorders including dementia"", Curr. Opin. Drug Discov. Development (2008), vol. 11, pp. 642-654.;;Kabalka et al., ""The Conversion of Phenols to the Corresponding Aryl Halides Under Mild Conditions,"" Synthesis (2005), vol. 4, pp. 547-550.;;Kohen et al., ""Cloning, Characterization, and Chromosomal Localization of a Human 5-Ht6 Serotonin Receptor"", J. Neurochemistry (1996), vol. 66, pp. 47-56.;;Kreis et al., ""A General and Efficient Method for the Synthesis of Silyl-Protected Arenethiol from Aryl Halides or Triflates,"" Adv. Synth. Catal. (2005), vol. 47, pp. 313-319.;;Macor et al., ""A Simple Synthesis of 5-Amino-3-(2-Dimethylaminoethyl)indole [5-amino-n,n-dimethyltryptamine]"", Synthetic Comm. (1993), vol. 23, pp. 65-72.;;Mitchell et al., ""5-HT6 receptors: a novel target for cognitive enhancement"", Pharmacology & Therapeutics (2005), vol. 108, pp. 320-333.;;Monsma et al., ""Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs,"" Molecular Pharmacology (1992), vol. 43, pp. 320-327.;;Morairty et al., ""Selective 5-HT2A and 5-HT6 Receptor Antagonists Promote Sleep in Rats,"" Sleep (2008), vol. 31, pp. 34-44.;;Morice et al., ""Synthesis of constrained arylpiperidines using intramolecular Heck or radical reactions,"" Tetrahedron Lett. (2001), vol. 42, pp. 6499-6502.;;Navari et al., ""Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial,"" Support Care Cancer (2009).;;Passik et al., ""A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain,"" J. Pain Symptom Manage (2002), vol. 23, pp. 526-532.;;Perez-Garcia et al., ""Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task,"" Pharmacology, Biochem. & Behavior (2005), vol. 81, pp. 673-682.;;Srivastava et al., ""Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer,"" J. Pain & Symptom Management (2003), vol. 25, pp. 578-582.;;Upton et al., ""5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease,"" J. Amer. Soc. Exper. NeuroTherapeutics (2008), vol. 5, pp. 458-469.;;Vogt et al., ""Investigation of the Human Serotonin 6 (5-HT6) Receptor Gene in Bipolar Affective Disorder and Schizophrenia,"" Amer. J. Med. Genetics (Neuropsychiatric Genetics) (2000), vol. 96, pp. 217-221.;;Wesolowska et al., ""Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression,"" Neuropharmcology (2007), vol. 52, pp. 1274-1283.;;Wood et al., ""Therapeutic potential of serotonin antagonists in depressive disorders,"" Expert Opin. Investig. Drugs (2002), vol. 11, pp. 457-467.;;Woolley et al., ""5-HT6 Receptors,"" Curr. Drug Targets-CNS & Neurological Disorders (2004), vol. 3, pp. 59-79.;;Yoshioka et al., ""Central Distribution and Function of 5-HT6 Receptor Subtype in the Rat Brain,"" Life Sci. (1998), vol. 62, pp. 1473-1477.;;Zuckerman et al., ""Sensation Seeking and Psychopathology,"" Psychiatry Res. (1979), vol. 1, pp. 255-264.",INACTIVE
128,US,A1,US 2010/0280007 A1,106-766-858-507-092,2010-11-04,2010,US 81580010 A,2010-06-15,US 81580010 A;;US 88100107 A;;US 83316406 P,2006-07-25,Pyridazinone Derivatives,"The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L,ALTO NEUROSCIENCE INC (2021-11-04);;CEPHALON INC (2010-05-03),https://lens.org/106-766-858-507-092,Patent Application,yes,43,9,47,47,0,C07D237/14;;C07D237/26;;C07D237/32;;C07D237/36;;C07D403/04;;C07D403/12;;C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/04;;A61P43/00;;A61P9/10;;C07D403/02;;C07D403/04;;C07D237/14;;C07D237/26;;C07D403/12;;C07D495/04;;C07D403/04;;C07D237/36;;C07D237/32;;C07D401/12;;C07D401/14;;C07D409/04;;C07D498/04,A61K31/55;;A61K31/501;;A61K31/502;;A61K31/5025;;A61K31/5377;;A61P1/00;;A61P3/04;;A61P9/10;;A61P11/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;A61P43/00;;C07D401/14;;C07D403/12;;C07D409/14;;C07D413/12;;C07D495/04;;C07D498/04,514/217.05;;514/236.5;;514/248;;514/252.03;;514/252.05;;540/599;;544/114;;544/234;;544/235;;544/236;;544/237;;544/238,0,0,,,,ACTIVE
129,US,A1,US 2010/0273779 A1,187-119-688-354-472,2010-10-28,2010,US 81581310 A,2010-06-15,US 81581310 A;;US 88100107 A;;US 83316406 P,2006-07-25,Pyridazinone Derivatives,"The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.",CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L,ALTO NEUROSCIENCE INC (2021-11-04);;CEPHALON INC (2010-05-03),https://lens.org/187-119-688-354-472,Patent Application,no,44,3,47,47,0,C07D237/14;;C07D237/26;;C07D237/32;;C07D237/36;;C07D403/04;;C07D403/12;;C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/04;;A61P43/00;;A61P9/10;;C07D403/02;;C07D403/04;;C07D237/14;;C07D237/26;;C07D403/12;;C07D495/04;;C07D403/04;;C07D237/36;;C07D237/32;;C07D401/12;;C07D401/14;;C07D409/04;;C07D498/04,A61K31/55;;A61K31/501;;A61K31/502;;A61P1/00;;A61P3/04;;A61P9/10;;A61P11/00;;A61P25/08;;A61P25/18;;A61P25/24;;A61P25/28;;A61P29/00;;C07D403/12;;C07D495/04,514/217.05;;544/238;;514/252.05;;514/252.03;;544/235;;514/248;;540/599,0,0,,,,ACTIVE
130,US,B2,US 8586588 B2,115-492-974-408-340,2013-11-19,2013,US 81581310 A,2010-06-15,US 81581310 A;;US 88100107 A;;US 83316406 P,2006-07-25,Aryl pyridazinone derivatives and their use as H3 receptor ligands,"The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H 3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.",BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L,ALTO NEUROSCIENCE INC (2021-11-04);;CEPHALON INC (2010-05-03),https://lens.org/115-492-974-408-340,Granted Patent,yes,100,2,47,47,0,C07D237/14;;C07D237/26;;C07D237/32;;C07D237/36;;C07D403/04;;C07D403/12;;C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/04;;A61P43/00;;A61P9/10;;C07D403/02;;C07D403/04;;C07D237/14;;C07D237/26;;C07D403/12;;C07D495/04;;C07D403/04;;C07D237/36;;C07D237/32;;C07D401/12;;C07D401/14;;C07D409/04;;C07D498/04,C07D403/12;;A61K31/501;;A61P3/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/24;;A61P29/00;;C07D401/14,514/252.03;;514/252.05;;544/238,64,49,022-205-540-150-665;;058-820-218-388-262;;049-037-304-790-636;;029-644-733-710-760;;138-204-722-096-876;;016-112-977-637-521;;129-557-353-970-763;;009-235-499-741-901;;129-413-384-828-353;;030-602-367-949-973;;023-259-843-875-399;;003-838-254-045-62X;;034-920-539-446-387;;028-061-122-694-174;;037-426-125-033-289;;082-451-059-342-222;;095-789-427-831-442;;053-083-013-814-994;;043-412-491-240-165;;033-810-769-059-776;;022-647-087-076-177;;034-230-903-602-246;;019-979-394-042-295;;033-497-186-604-658;;093-787-384-820-02X;;001-057-832-214-452;;078-619-918-873-833;;102-631-514-261-830;;012-058-136-528-355;;029-154-561-518-729;;060-537-779-460-47X;;000-206-887-384-58X;;005-359-431-101-405;;009-550-404-283-996;;092-049-659-431-656;;000-147-277-511-193;;023-527-249-690-285;;015-504-557-455-090;;028-479-713-064-439;;091-285-213-055-041;;091-285-213-055-041;;055-010-736-121-070;;146-610-741-548-827;;026-922-462-735-517;;023-346-432-262-964;;036-121-275-120-173;;012-082-660-480-298;;001-057-832-214-452;;035-019-845-344-906,10.2174/1568007033482760;;14529362;;10.1038/302832a0;;6188956;;16376822;;10.1016/s1359-6446(05)03625-1;;11890359;;11501041;;10.1124/mi.6.2.5;;16565470;;10.1016/s0166-4328(01)00379-5;;11844582;;10.1124/jpet.102.047241;;12606600;;14550847;;10.1016/j.lfs.2003.06.003;;10.1517/13543784.13.10.1237;;15461554;;10.1007/s00213-003-1431-0;;12682709;;9652190;;10.1016/s0165-6147(98)01201-2;;10.1038/nrd1631;;15665857;;2169324;;10.1016/0006-8993(90)91508-e;;10640281;;8797189;;10.1016/0893-133x(95)00151-3;;11862340;;10.1007/s002130100892;;12196593;;pmc6757981;;10.1523/jneurosci.22-17-07695.2002;;10.1016/j.tips.2004.10.003;;15530639;;10.1007/s11882-003-0044-3;;12662472;;15078574;;10.1111/j.1460-9568.2004.03251.x;;15341517;;10.1111/j.1471-4159.2004.02606.x;;10.1016/s0166-4328(03)00091-3;;12946612;;10.1016/j.pharmthera.2004.05.001;;15251226;;14660004;;10.1016/j.ejphar.2003.09.072;;10.1021/jm030776l;;12723963;;10.1021/jm00385a003;;3027337;;3208896;;9353396;;10.1016/0031-9384(82)90201-3;;7048358;;4764313;;10.1016/0006-8993(73)90120-0;;9808693;;8384565;;10.1016/0014-2999(93)90733-x;;3228475;;10.1016/0166-4328(88)90157-x;;10.1037//0735-7036.96.6.1000;;10.1021/jm00390a007;;3599022;;10.1002/jhet.5570110518;;15739896;;9060901;;10.1016/s0735-1097(96)00534-7;;10.1248/cpb.44.2061;;8945771;;10.1248/cpb.44.2061;;8945771;;2848100;;10.1007/bf01676955;;10.1021/jm00329a029;;2213839;;10.1021/jm00172a031;;2822926;;10.1021/jm00394a005;;10.1055/s-1993-25861;;11472206;;10.1021/jm010838c;;10.1021/jm030776l;;12723963;;10.1002/jlcr.2580220902,"Alguacil, L.F. et al., Histamine H3 Receptor: A potential drug target for the treatment of central nervous system disorders. Current Drug Targets-CNS & Neurological Disorders 2003, 2, 303-131.;;Arrang, J. M. et al., Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302, (5911), 832-7.;;Celanire, S. et al., Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov. Today 2005, 10, (23-24), 1613-27.;;Chazot, P.L. et al., H3 histamine receptor isoforms: New therapeutic targets in the CNS? Current Opinions in Investigational Drugs 2001, 2, 1428-1431.;;Chen, Z. Effect of histamine H3-receptor antagonist clobenprobit on spatial memory of radial maze performance in rats. Acta Pharmacol. Sin. 2000, 21, 905-910.;;Esbenshade, T.A. et al., Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Molecular interventions 2006, 6, 77-88.;;Fox, G.B. et al., Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition response in the spontaneously hypertensive rat pup. Behav. Brain Res. 2002, 131, 151-161.;;Fox, G.B. et al., Two novel and selective nonimidazole H3 receptor Antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exper. Ther. 2003, 305, 897-908.;;Hancock, A.A. et al., Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci. 2003, 73, (24), 3043-72.;;Hancock, A.A. et al., Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs, 2004, 13, 1237-1248.;;Komater, V.A. et al., H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology 2003, 167, 363-372.;;Leurs, R. et al., Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends in Pharmacology 1998, 19, 177-183.;;Leurs, R. et al., The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. 2005, 4, (2), 107-20.;;Lin, J. S. et al., Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res. 1990, 523, (2), 325-30.;;Lloyd, G.K. et al., Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 2000, 292, 461-467.;;Monti, J.M. et al., Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996, 15, 31-5.;;Orsetti, M. et al., Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory. Psychopharmacology 2002, 159, 133-137.;;Parmentier, R. et al., Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 2002, 22, 7695-7711.;;Passani, M.B. et al., The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. 2004, 25, 618-25.;;Repka-Ramirez, M.S. New concepts of histamine receptors and actions. Current Allergy and Asthma Reports 2003, 3, 227-231.;;Ritz, A. et al., J. Anxiety and cognition in histamine H3 receptor -/- mice. Eur. J. Neurosci. 2004, 19, 1992-1996.;;Rouleau, A. et al., Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. J. Neurochem. 2004, 90, 1331-8.;;Vanni-Merci, G. et al., Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. Behav. Brain Res. 2003, 144, 227-241.;;Witkin, J. M. et al., Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol. Ther. 2004, 103, 1-20.;;Yao, B. B. et al., Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur. J. Pharmacol. 2003, 482, (1-3), 49-60.;;Lehninger, A.L. Biochemistry, 2'd ed.; Worth Publishers: New York, 1975; 71-77.;;Heterocycles, 2002, 57, 39.;;Chem. Pharm. Bull., 1980, 42, 1850.;;Van der Mey, M. et al. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents, J. Med. Chem. 2003, 46, 2008-2016.;;Indian J. Chem, 1977, 16B, 631.;;Wermuth, C.G. et al., Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of .gamma.-aminobutyric acid acting as selective GABA-A antagonists, J. Med. Chem., 1987, 30, 239-249.;;Pinna, G.A. et al., Synthesis and Pharmacological Study of 5-aryl-6-methyl-4,5-dihydro-pyridazin-3(2H)ones and related 5-aryl-6-methyl-pyridazin-3(2H)ones, Farmaco, 1987, 43, 539-549.;;Genbank file #NM-053506.;;Edgar & Seidel, Journal of Pharmacology and Experimental Therapeutics, 283: 757-769, 1997.;;Kraly, F.S. et al., 1982 Physiol. Behay. 28: 841.;;Leibowitz, S.F. 1973 Brain Res. 63:440.;;Ligneau, X. et al., 1998 J. Pharmcol. Exp. Ther. 287:658-66.;;Clapham, J. and Kilpatrick G.J. 1993 Eur. J. Pharmacol. 232:99-103.;;Ennaceur, A. and Delacour, J. (1988) Behay. Brain Res. 31: 47-59.;;Thor and Holloway (1982). Thor, D. And Holloway, W. (1982) J. Comp. Physiolog. Psychcol. 96: 1000-1006.;;Okushima, Hiromi et al., ""A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives,"" J. Med. Chem., 1987, 30(7), 1157-1161.;;Steck, Edgar A. et al., ""Pyridazines. VI. 6 Substituted 3(2H)pyridazinones,"" J. Heterocyclic Chem., 1974, 11(5), 755-761.;;Li, Wenxin et al., ""Synthesis and platelet aggregation inhibitory activity of 6-(4-substituted phenyl-4,5-dihydro-3-(2H)-pyridazinones,"" Zhongguo Yaowu Huaxue Zazhi, 1997, 7(1), 12-17.;;Zhu, Jin et al., ""Synthesis and platelet aggregation inhibitory activity of 4,5-dihydro-3(2H)- pyridazinones,"" Zhongguo Yaowu Huaxue Zazhi, 2004, 14(1), 23-26.;;Xu, Youjun et al., ""Synthesis and platelet aggregation inhibitory activity of 6-(substituted phenyl)-4,5-dihydro-3(2H)-pryidazinones,"" Zhongguo Yaowu Huaxue Zazhi, 1997, 7(4), 240-245.;;Apelt, J. et al., ""Search for histamine H3 receptor antagonists with combined inhibitory potency at N -methyltransferase: ether derivatives,"" Pharmazie, Die, Govi Verlag, Eschborn, DE, vol. 60, No. 2, 2005, pp. 97-106.;;Mori et al., ""Oxygen-Saving Effect of a New Cardiotonic Agent, MCI-154, in Diseased Human Hearts"", J. Am. Coll. Cardiol. (1997), 29(3), 613-622.;;Seki, et al., ""Studies on Agents with Vasodilator and beta-Blocking Activities. IV"", Chem. Pharm. Bull. (1996), 44(11), 2061-2069.;;Seki et al., ""Studies on Agents with Vasodilator and B-Blocking Activities. IV"", Chem. Pharm. Bull. (1996), vol. 44(11), pp. 2061-2069.;;Davis et al., ""Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors"", J. Computer-Aided Mol. Design (1987), vol. 1, pp. 97-120.;;Loynes et al., ""New Sulfonamides"", J. Med. Chem. (1965), vol. 8(5), pp. 691-694.;;Mertens et al., ""Nonsteroidal Cardiotonics. 3. New 4,5-Dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and Related Compounds with Positive Inotropic Activities"", J. Med. Chem. (1990), vol. 33, pp. 2870-2875.;;Sircar, ""Cardiotonic Agents. 7. Inhibition of Separated Forms of Cyclic Nucleotide Phosphodiesterase from Guinea Pig Cardiac Muscle by 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and Related Compounds. Structure-Activity Relationships and Correlation with in Vivo Positive Inotropic Activity"", J. Med. Chem. (1987), vol. 30, pp. 1955-1962.;;Coates et al., ""One-Pot Preparation of 6-Substituted 3(2H-Pyridazinones from Ketones"", Synthesis (1993), pp. 334-342.;;Van der Mey et al., ""Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure-Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones"", J. Med. Chem. (2001), vol. 44, pp. 2523-2535.;;Van der Mey et al., ""Synthesis and Structure-Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents"", J. Med. Chem. (2003), vol. 46, pp. 2008-2016.;;Saunders et al., ""Syntheses of carbon-14-labeled prizidilol dihydrochloride"", J. Labelled Compounds and Radiopharmaceuticals (1985), vol. 22(9), pp. 869-881 (Abstract only).;;Shang et al., ""Investigation on exposy resin adhesive containing phthalazinone"", Zhongguo Jiaoniangi (2002), vol. 11 (2), pp. 1-3 (Abstract only).;;Kuehmstedt et al., ""Synthesis of tetrahydropyranyl and tetrahydrofuryl derivatives of various 3-pyridazones and 3-thiopyridazones"", Zeitschrift fuer Chemie (1965), vol. 5(7), pp. 269-270 (Abstract only).;;Eurasian Office Action for EA Appln. No. 200970156/28 dated Sep. 21, 2010 (English translation included).;;European Communication for EP Appln. No. 07810758.8-2117 dated Dec. 8, 2009.;;Singapore Office Action for SG Appln. No. 200900331-0 dated Oct. 22, 2010.;;New Zealand Office Action for NZ Appln. No. 574873 dated Jul. 16, 2010.;;China Office Action for CN Appln. No. 200780034555.6 dated Nov. 22, 2010 (English translation included).",ACTIVE
131,US,A1,US 2011/0288075 A1,104-766-015-773-277,2011-11-24,2011,US 201113197243 A,2011-08-03,US 201113197243 A;;US 81580010 A;;US 88100107 A;;US 83316406 P,2006-07-25,Pyridazinone Derivatives,"The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.",BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L,ALTO NEUROSCIENCE INC (2021-11-04);;CEPHALON INC (2010-05-03),https://lens.org/104-766-015-773-277,Patent Application,yes,0,1,47,47,0,C07D237/14;;C07D237/26;;C07D237/32;;C07D237/36;;C07D403/04;;C07D403/12;;C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/04;;A61P43/00;;A61P9/10;;C07D403/02;;C07D403/04;;C07D237/14;;C07D237/26;;C07D403/12;;C07D495/04;;C07D403/04;;C07D237/36;;C07D237/32;;C07D401/12;;C07D401/14;;C07D409/04;;C07D498/04,A61K31/55;;A61K31/50;;A61K31/501;;A61K31/502;;A61K31/5025;;A61K31/5377;;A61P25/00;;A61P25/18;;A61P25/28,514/217.05;;514/252.03;;514/252.05;;514/248;;514/236.5;;514/247,3,3,066-924-580-489-468;;003-838-254-045-62X;;001-814-397-576-306,12182878;;10.1016/s0960-894x(02)00521-8;;9652190;;10.1016/s0165-6147(98)01201-2;;17327487;;10.1124/jpet.107.120311,"Ting, et al., Bioorganic & Medicinal Chemistry Letters, 12 (2002) 2643-2646;;Leurs, et al., TiPS - May 1998 (Vol. 19), 177-183;;Medhurst, et al., J. Pharmacol. & Experiment. Therapeut., Vol. 321, No. 3, 1032-1045",ACTIVE
132,US,A1,US 2014/0142088 A1,183-281-325-983-464,2014-05-22,2014,US 201314083013 A,2013-11-18,US 201314083013 A;;US 81581310 A;;US 88100107 A;;US 83316406 P,2006-07-25,PYRIDAZINONE DERIVATIVES,"The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.",BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALISON L;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALISON L,,https://lens.org/183-281-325-983-464,Patent Application,yes,0,1,47,47,0,C07D237/14;;C07D237/26;;C07D237/32;;C07D237/36;;C07D403/04;;C07D403/12;;C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/04;;A61P43/00;;A61P9/10;;C07D403/02;;C07D403/04;;C07D237/14;;C07D237/26;;C07D403/12;;C07D495/04;;C07D403/04;;C07D237/36;;C07D237/32;;C07D401/12;;C07D401/14;;C07D409/04;;C07D498/04,C07D498/04;;C07D237/14;;C07D237/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D409/04;;C07D495/04,514/217.05;;544/238;;514/252.05;;514/252.03;;544/235;;514/248;;540/599;;544/234;;544/236;;544/114;;514/236.5,0,0,,,,DISCONTINUED
133,US,B2,US 8673916 B2,032-182-276-601-853,2014-03-18,2014,US 201113197243 A,2011-08-03,US 201113197243 A;;US 81580010 A;;US 88100107 A;;US 83316406 P,2006-07-25,Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives,"The present invention is directed to methods of treating disorders mediated by Histamine H 3 receptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H 3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.",BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK D;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L;;CEPHALON INC,BACON EDWARD R;;BAILEY THOMAS R;;BECKNELL NADINE C;;CHATTERJEE SANKAR;;DUNN DEREK D;;HOSTETLER GREG A;;HUDKINS ROBERT L;;JOSEF KURT A;;KNUTSEN LARS J S;;TAO MING;;ZULLI ALLISON L,ALTO NEUROSCIENCE INC (2021-11-04);;CEPHALON INC (2010-05-03),https://lens.org/032-182-276-601-853,Granted Patent,yes,99,2,47,47,0,C07D237/14;;C07D237/26;;C07D237/32;;C07D237/36;;C07D403/04;;C07D403/12;;C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61P3/00;;A61P3/04;;A61P43/00;;A61P9/10;;C07D403/02;;C07D403/04;;C07D237/14;;C07D237/26;;C07D403/12;;C07D495/04;;C07D403/04;;C07D237/36;;C07D237/32;;C07D401/12;;C07D401/14;;C07D409/04;;C07D498/04,A61P3/04;;A61K31/501;;A61P25/06;;A61P25/08;;A61P25/18;;A61P25/24;;A61P25/28,514/252.05,68,52,066-924-580-489-468;;003-838-254-045-62X;;001-814-397-576-306;;091-285-213-055-041;;055-010-736-121-070;;146-610-741-548-827;;026-922-462-735-517;;023-346-432-262-964;;036-121-275-120-173;;012-082-660-480-298;;001-057-832-214-452;;035-019-845-344-906;;022-205-540-150-665;;058-820-218-388-262;;049-037-304-790-636;;029-644-733-710-760;;138-204-722-096-876;;016-112-977-637-521;;129-557-353-970-763;;009-235-499-741-901;;129-413-384-828-353;;030-602-367-949-973;;023-259-843-875-399;;003-838-254-045-62X;;034-920-539-446-387;;028-061-122-694-174;;037-426-125-033-289;;082-451-059-342-222;;095-789-427-831-442;;053-083-013-814-994;;043-412-491-240-165;;033-810-769-059-776;;022-647-087-076-177;;034-230-903-602-246;;019-979-394-042-295;;033-497-186-604-658;;093-787-384-820-02X;;001-057-832-214-452;;078-619-918-873-833;;102-631-514-261-830;;012-058-136-528-355;;029-154-561-518-729;;060-537-779-460-47X;;000-206-887-384-58X;;005-359-431-101-405;;009-550-404-283-996;;092-049-659-431-656;;000-147-277-511-193;;023-527-249-690-285;;015-504-557-455-090;;028-479-713-064-439;;091-285-213-055-041,12182878;;10.1016/s0960-894x(02)00521-8;;9652190;;10.1016/s0165-6147(98)01201-2;;17327487;;10.1124/jpet.107.120311;;10.1248/cpb.44.2061;;8945771;;2848100;;10.1007/bf01676955;;10.1021/jm00329a029;;2213839;;10.1021/jm00172a031;;2822926;;10.1021/jm00394a005;;10.1055/s-1993-25861;;11472206;;10.1021/jm010838c;;10.1021/jm030776l;;12723963;;10.1002/jlcr.2580220902;;10.2174/1568007033482760;;14529362;;10.1038/302832a0;;6188956;;16376822;;10.1016/s1359-6446(05)03625-1;;11890359;;11501041;;10.1124/mi.6.2.5;;16565470;;10.1016/s0166-4328(01)00379-5;;11844582;;10.1124/jpet.102.047241;;12606600;;14550847;;10.1016/j.lfs.2003.06.003;;10.1517/13543784.13.10.1237;;15461554;;10.1007/s00213-003-1431-0;;12682709;;9652190;;10.1016/s0165-6147(98)01201-2;;10.1038/nrd1631;;15665857;;2169324;;10.1016/0006-8993(90)91508-e;;10640281;;8797189;;10.1016/0893-133x(95)00151-3;;11862340;;10.1007/s002130100892;;12196593;;pmc6757981;;10.1523/jneurosci.22-17-07695.2002;;10.1016/j.tips.2004.10.003;;15530639;;10.1007/s11882-003-0044-3;;12662472;;15078574;;10.1111/j.1460-9568.2004.03251.x;;15341517;;10.1111/j.1471-4159.2004.02606.x;;10.1016/s0166-4328(03)00091-3;;12946612;;10.1016/j.pharmthera.2004.05.001;;15251226;;14660004;;10.1016/j.ejphar.2003.09.072;;10.1021/jm030776l;;12723963;;10.1021/jm00385a003;;3027337;;3208896;;9353396;;10.1016/0031-9384(82)90201-3;;7048358;;4764313;;10.1016/0006-8993(73)90120-0;;9808693;;8384565;;10.1016/0014-2999(93)90733-x;;3228475;;10.1016/0166-4328(88)90157-x;;10.1037//0735-7036.96.6.1000;;10.1021/jm00390a007;;3599022;;10.1002/jhet.5570110518;;15739896;;9060901;;10.1016/s0735-1097(96)00534-7;;10.1248/cpb.44.2061;;8945771,"Ting, et al., Bioorganic & Medicinal Chemistry Letters, 12 (2002) 2643-2646.;;Leurs, et al., TiPS-May 1998 (vol. 19), 177-183.;;Medhurst, et al., J. Pharmacol. & Experiment. Therapeut., vol. 321, No. 3, 1032-1045.;;Seki et al., ""Studies on Agents with Vasodilator and B-Blocking Activities. IV"", Chem. Pharm. Bull. (1996), vol. 44(11), pp. 2061-2069.;;Davis et al., ""Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors"", J. Computer-Aided Mol. Design (1987), vol. 1, pp. 97-120.;;Loynes et al., ""New Sulfonamides"", J. Med. Chem. (1965), vol. 8(5), pp. 691-694.;;Mertens et al., ""Nonsteroidal Cardiotonics. 3. New 4,5-Dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and Related Compounds with Positive Inotropic Activities"", J. Med. Chem. (1990), vol. 33, pp. 2870-2875.;;Sircar, ""Cardiotonic Agents. 7. Inhibition of Separated Forms of Cyclic Nucleotide Phosphodiesterase from Guinea Pig Cardiac Muscle by 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and Related Compounds. Structure-Activity Relationships and Correlation with in Vivo Positive Inotropic Activity"", J. Med. Chem. (1987), vol. 30, pp. 1955-1962.;;Coates et al., ""One-Pot Preparation of 6-Substituted 3(2H-Pyridazinones from Ketones"", Synthesis (1993), pp. 334-342.;;Van der Mey et al., ""Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure-Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones"", J. Med. Chem. (2001), vol. 44, pp. 2523-2535.;;Van der Mey et al., ""Synthesis and Structure-Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents"", J. Med. Chem. (2003), vol. 46, pp. 2008-2016.;;Saunders et al., ""Syntheses of carbon-14-labeled prizidilol dihydrochloride"", J. Labelled Compounds and Radiopharmaceuticals (1985), vol. 22(9), pp. 869-881 (Abstract only).;;Shang et al., ""Investigation on exposy resin adhesive containing phthalazinone"", Zhongguo Jiaoniangi (2002), vol. 11 (2), pp. 1-3 (Abstract only).;;Kuehmstedt et al., ""Synthesis of tetrahydropyranyl and tetrahydrofuryl derivatives of various 3-pyridazones and 3-thiopyridazones"", Zeitschrift fuer Chemie (1965), vol. 5(7), pp. 269-270 (Abstract only).;;Eurasian Office Action for EA Appln. No. 200970156/28 dated Sep. 21, 2010 (English translation included).;;European Communication for EP Appln. No. 07810758.8-2117 dated Dec. 8, 2009.;;Singapore Office Action for SG Appln. No. 200900331-0 dated Oct. 22, 2010.;;New Zealand Office Action for NZ Appln. No. 574873 dated Jul. 16, 2010.;;China Office Action for CN Appln. No. 200780034555.6 dated Nov. 22, 2010 (English translation included).;;Alguacil, L.F. et al., Histamine H3 Receptor: A potential drug target for the treatment of central nervous system disorders. Current Drug Targets-CNS & Neurological Disorders 2003, 2, 303-131.;;Arrang, J. M. et al., Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302, (5911), 832-7.;;Celanire, S. et al., Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov. Today 2005, 10, (23-24), 1613-27.;;Chazot, P.L. et al., H3 histamine receptor isoforms: New therapeutic targets in the CNS? Current Opinions in Investigational Drugs 2001, 2, 1428-1431.;;Chen, Z. Effect of histamine H3-receptor antagonist clobenprobit on spatial memory of radial maze performance in rats. Acta Pharmacol. Sin. 2000, 21, 905-910.;;Esbenshade, T.A. et al., Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Molecular interventions 2006, 6, 77-88.;;Fox, G.B. et al., Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition response in the spontaneously hypertensive rat pup. Behav. Brain Res. 2002, 131, 151-161.;;Fox, G.B. et al., Two novel and selective nonimidazole H3 receptor Antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exper. Ther. 2003, 305, 897-908.;;Hancock, A.A. et al., Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci. 2003, 73, (24), 3043-72.;;Hancock, A.A. et al., Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs, 2004, 13, 1237-1248.;;Komater, V.A. et al., H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology 2003, 167, 363-372.;;Leurs, R. et al., Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends in Pharmacology 1998, 19, 177-183.;;Leurs, R. et al., The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. 2005, 4, (2), 107-20.;;Lin, J. S. et al., Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res. 1990, 523, (2), 325-30.;;Lloyd, G.K. et al., Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 2000, 292, 461-467.;;Monti, J.M. et al., Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996, 15, 31-5.;;Orsetti, M. et al., Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory. Psychopharmacology 2002, 159, 133-137.;;Parmentier, R. et al., Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 2002, 22, 7695-7711.;;Passani, M.B. et al., The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. 2004, 25, 618-25.;;Repka-Ramirez, M.S. New concepts of histamine receptors and actions. Current Allergy and Asthma Reports 2003, 3, 227-231.;;Ritz, A. et al., J. Anxiety and cognition in histamine H3 receptor -/- mice. Eur. J. Neurosci. 2004, 19, 1992-1996.;;Rouleau, A. et al., Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. J. Neurochem. 2004, 90, 1331-8.;;Vanni-Merci, G. et al., Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. Behav. Brain Res. 2003, 144, 227-241.;;Witkin, J. M. et al., Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol. Ther. 2004, 103, 1-20.;;Yao, B. B. et al., Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur. J. Pharmacol. 2003, 482, (1-3), 49-60.;;Lehninger, A.L. Biochemistry, 2'd ed.; Worth Publishers: New York, 1975; 71-77.;;Heterocycles, 2002, 57, 39.;;Chem. Pharm. Bull., 1980, 42, 1850.;;Van der Mey, M. et al. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents, J. Med. Chem. 2003, 46, 2008-2016.;;Indian J. Chem, 1977, 16B, 631.;;Wermuth, C.G. et al., Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of .gamma.-aminobutyric acid acting as selective GABA-A antagonists, J. Med. Chem., 1987, 30, 239-249.;;Pinna, G.A. et al., Synthesis and Pharmacological Study of 5-aryl-6-methyl-4,5-dihydro-pyridazin-3(2H)ones and related 5-aryl-6-methyl-pyridazin-3(2H)ones, Farmaco, 1987, 43, 539-549.;;Genbank file #NM-053506.;;Edgar & Seidel, Journal of Pharmacology and Experimental Therapeutics, 283: 757-769, 1997.;;Kraly, F.S. et al., 1982 Physiol. Behav. 28: 841.;;Leibowitz, S.F. 1973 Brain Res. 63:440.;;Ligneau, X. et al., 1998 J. Pharmcol. Exp. Ther. 287:658-66.;;Clapham, J. and Kilpatrick G.J. 1993 Eur. J. Pharmacol. 232:99-103.;;Ennaceur, A. and Delacour, J. (1988) Behav. Brain Res. 31: 47-59.;;Thor and Holloway (1982). Thor, D. and Holloway, W. (1982) J. Comp. Physiolog. Psychcol. 96: 1000-1006.;;Okushima, Hiromi et al., ""A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives,"" J. Med. Chem., 1987, 30(7), 1157-1161.;;Steck, Edgar A. et al., ""Pyridazines. VI. 6 Substituted 3(2H)pyridazinones,"" J. Heterocyclic Chem., 1974, 11(5), 755-761.;;Li, Wenxin et al., ""Synthesis and platelet aggregation inhibitory activity of 6-(4-substituted phenyl-4,5-dihydro-3-(2H)-pyridazinones,"" Zhongguo Yaowu Huaxue Zazhi, 1997, 7(1), 12-17.;;Zhu, Jin et al., ""Synthesis and platelet aggregation inhibitory activity of 4,5-dihydro-3(2H)-pyridazinones,"" Zhongguo Yaowu Huaxue Zazhi, 2004, 14(1), 23-26.;;Xu, Youjun et al., ""Synthesis and platelet aggregation inhibitory activity of 6-(substituted phenyl)-4,5-dihydro-3(2H)-pryidazinones,"" Zhongguo Yaowu Huaxue Zazhi, 1997, 7(4), 240-245.;;Apelt, J. et al., ""Search for histamine H3 receptor antagonists with combined inhibitory potency at N-methyltransferase: ether derivatives,"" Pharmazie, Die, Govi Verlag, Eschborn, DE, vol. 60, No. 2, 2005, pp. 97-106.;;Mori et al., ""Oxygen-Saving Effect of a New Cardiotonic Agent, MCI-154, in Diseased Human Hearts"", J. Am. Coll. Cardiol. (1997), 29(3), 613-622.;;Seki, et al., ""Studies on Agents with Vasodilator and beta-Blocking Activities. IV"", Chem. Pharm. Bull. (1996), 44(11), 2061-2069.;;Genbank file #NM 053506 (Jan. 25, 2009).",ACTIVE
134,EP,A1,EP 2571697 A1,088-449-265-884-482,2013-03-27,2013,EP 11782764 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,,ZAMTEC LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN,ZAMTEC LIMITED (2014-02-12);;MEMJET TECHNOLOGY LIMITED (2014-09-24);;MEMJET TECHNOLOLGY LIMITED (2014-08-13),https://lens.org/088-449-265-884-482,Patent Application,yes,0,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/165;;B41J2/175;;B41J2/18,,0,0,,,,ACTIVE
135,EP,A3,EP 3132941 A3,055-791-863-348-571,2017-11-08,2017,EP 16189612 A,2011-05-16,US 34557210 P;;EP 11782764 A;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,"A system for distributing fluid and gas within a printer is provided having a fluid container (310) having three fluid ports (311), a first fluid path (380) connecting the first fluid port (313) to a printhead (200) of the printer, a second fluid path (382) connecting the second fluid port (315) to the printhead, and a third fluid path (333) connecting the third fluid port (317) to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.
",MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/055-791-863-348-571,Search Report,yes,1,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/165;;B41J2/175;;B41J2/18,,0,0,,,,ACTIVE
136,AU,A1,AU 2014/256352 A1,092-108-539-431-034,2014-11-20,2014,AU 2014/256352 A,2014-10-29,AU 2013/216640 A;;AU 2014/256352 A,2013-08-15,INKJET PRINTER HAVING DUAL VALVE ARRANGEMENT,"A method of de-priming an inkjet printhead having a first port and a second port, 20 the inkjet printhead being contained in an inkjet printer comprising: an ink container having an outlet port and a return port; a first ink line interconnecting the first port with the outlet port; a second ink line interconnecting the second port with the return port; an air line connected to the first ink line, the air line having an inlet open to 25 atmosphere; a reversible pump positioned between the second port and the return port for pumping ink in the second ink line; and a dual valve arrangement comprising: a first valve for selectively controlling ink flow through the first ink line, the 30 first valve being positioned in the first ink line between the ink container and the air line; and a second valve for selectively controlling air flow through the air line, the method comprising the steps of: (i) closing the first valve and opening the second valve; and (ii) pumping ink in the second ink line from the second port towards the return port, thereby drawing air through printhead from the air line and de-priming the printhead.",MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILLIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/092-108-539-431-034,Patent Application,no,0,0,2,2,0,,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
137,KR,A,KR 20130120373 A,102-383-967-754-603,2013-11-04,2013,KR 20127032533 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,,ZAMTEC LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE WATTS EDWARD ELLIS,,https://lens.org/102-383-967-754-603,Patent Application,no,0,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/18;;B41J2/19,,0,0,,,,ACTIVE
138,JP,A,JP 2016013696 A,014-121-144-355-02X,2016-01-28,2016,JP 2015157291 A,2015-08-07,US 34557210 P,2010-05-17,SYSTEM FOR ALLOCATING FLUID AND GAS IN PRINTER,"PROBLEM TO BE SOLVED: To provide a fluid allocation system which maintains a print environment of a print head.SOLUTION: A fluid allocation system 300 of a print head 200 includes a supply cartridge 301 having three fluid ports, a first fluid passage which connects the first fluid port to the print head 200 of a printer, a second fluid passage which connects the second fluid port to the print head, and a third fluid passage which connects the third fluid port to a gas vent hole 315. The first and second fluid ports for allocating a fluid and gas in the printer is so structured that the fluid from the supply cartridge 301 flows between the first fluid passage and the second fluid passage through the print head 200. The third fluid port is so structured that the gas flows between the supply cartridge 301 and the gas vent hole 315.",MERNJET TECHNOLOGY LTD,ERIC JOHNSON;;GAO JINSONG;;ANDY BOUND;;THOMAS ROETKER;;JON OLSON;;JON LUCAS;;RYAN ROOT;;PAUL FISHBEIN;;PAUL SEITER;;GREG WILLIAMS;;JOHN BAILEY;;BOB YRACEBURU;;PAUL WEISKOPF;;VICTOR ESCOBEDO;;RICHARD ALAN KELLEY;;JOHN CHRISTIAN LOVE;;JEFFREY D LUESCHEN;;JEFFREY JOHNSON;;CHRISTOPHER HIBBARD;;KENT BENJAMEN KWAN;;GEOFFREY PHILIP DYER;;EDWARD ELLIS ESDAILE-WATTS,,https://lens.org/014-121-144-355-02X,Patent Application,no,15,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/18;;B41J2/165;;B41J2/175,,0,0,,,,ACTIVE
139,CN,A,CN 103038064 A,180-382-297-286-234,2013-04-10,2013,CN 201180035226 A,2011-05-16,AU 2011/000572 W;;US 34557210 P,2010-05-17,System for distributing fluid and gas within printer,"A system for distributing fluid and gas within a printer is provided having a fluid container having three fluid ports, a first fluid path connecting the first fluid port to a printhead of the printer, a second fluid path connecting the second fluid port to the printhead, and a third fluid path connecting the third fluid port to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.",ZAMTEC CO LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/180-382-297-286-234,Patent Application,no,8,14,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
140,EP,B1,EP 3132941 B1,066-113-720-007-936,2019-11-13,2019,EP 16189612 A,2011-05-16,US 34557210 P;;EP 11782764 A;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,,MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/066-113-720-007-936,Granted Patent,yes,1,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/165;;B41J2/175;;B41J2/18,,0,0,,,,ACTIVE
141,AU,B2,AU 2014/256352 B2,053-055-522-253-920,2015-10-29,2015,AU 2014/256352 A,2014-10-29,AU 2013/216640 A;;AU 2014/256352 A,2013-08-15,INKJET PRINTER HAVING DUAL VALVE ARRANGEMENT,"A method of de-priming an inkjet printhead having a first port and a second port, 20 the inkjet printhead being contained in an inkjet printer comprising: an ink container having an outlet port and a return port; a first ink line interconnecting the first port with the outlet port; a second ink line interconnecting the second port with the return port; an air line connected to the first ink line, the air line having an inlet open to 25 atmosphere; a reversible pump positioned between the second port and the return port for pumping ink in the second ink line; and a dual valve arrangement comprising: a first valve for selectively controlling ink flow through the first ink line, the 30 first valve being positioned in the first ink line between the ink container and the air line; and a second valve for selectively controlling air flow through the air line, the method comprising the steps of: (i) closing the first valve and opening the second valve; and (ii) pumping ink in the second ink line from the second port towards the return port, thereby drawing air through printhead from the air line and de-priming the printhead.",MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILLIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/053-055-522-253-920,Granted Patent,no,2,0,2,2,0,,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
142,CN,A,CN 105667095 A,128-852-074-841-550,2016-06-15,2016,CN 201610008938 A,2011-05-16,US 34557210 P;;CN 201180035226 A,2010-05-17,System for distributing fluid and gas within printer,"A system for distributing fluid and gas within a printer is provided having a fluid container having three fluid ports, a first fluid path connecting the first fluid port to a printhead of the printer, a second fluid path connecting the second fluid port to the printhead, and a third fluid path connecting the third fluid port to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.",MAXJET TECH CO LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/128-852-074-841-550,Patent Application,no,8,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
143,AU,B2,AU 2011/256127 B2,148-428-761-192-866,2013-05-30,2013,AU 2011/256127 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,System for distributing fluid and gas within printer,"A system for distributing fluid and gas within a printer is provided having a fluid container having three fluid ports, a first fluid path connecting the first fluid port to a printhead of the printer, a second fluid path connecting the second fluid port to the printhead, and a third fluid path connecting the third fluid port to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.",MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/148-428-761-192-866,Granted Patent,no,2,1,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
144,AU,A1,AU 2013/216640 A1,050-909-356-265-420,2013-08-29,2013,AU 2013/216640 A,2013-08-15,AU 2011/256127 A;;AU 2013/216640 A,2011-05-16,SYSTEM FOR REDUCING INK COLOR MIXING EFFECTS IN PRINTER,"Abstract A system for reducing ink color mixing effects in a printer. The system includes: a printhead having multiple ink color channels, the printhead being mounted within the printer at a first level; and a plurality of ink containers mounted within the printer so as to be fluidically connected to the printhead, the plurality of ink containers being positioned in an array having a plurality of levels which are lower than the first level. The plurality of ink containers includes: a black ink container which supplies black colored ink to a black ink color channel of the printhead, the black ink container being disposed at the lowest level defined by the array; and a yellow ink container which supplies yellow colored ink to a yellow ink color channel of the printhead, the yellow ink container being disposed at the highest level defined by the array.",ZAMTEC LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/050-909-356-265-420,Patent Application,no,0,0,2,2,0,,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
145,SG,A,SG 10201502832Y A,173-252-557-295-104,2015-05-28,2015,SG 10201502832Y A,2011-05-16,US 34557210 P,2010-05-17,System For Distributing Fluid And Gas Within Printer,,MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/173-252-557-295-104,Unknown,no,0,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,,,0,0,,,,PENDING
146,SG,A1,SG 185565 A1,197-893-499-375-333,2012-12-28,2012,SG 2012083713 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,"A system for distributing fluid and gas within a printer is provided having a fluid container having three fluid ports, a first fluid path connecting the first fluid port to a printhead of the printer, a second fluid path connecting the second fluid port to the printhead, and a third fluid path connecting the third fluid port to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.",ZAMTEC LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/197-893-499-375-333,Patent Application,no,0,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,,,0,0,,,,PENDING
147,WO,A1,WO 2011/143698 A1,092-473-202-619-977,2011-11-24,2011,AU 2011/000572 W,2011-05-16,US 34557210 P,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,"A system for distributing fluid and gas within a printer is provided having a fluid container having three fluid ports, a first fluid path connecting the first fluid port to a printhead of the printer, a second fluid path connecting the second fluid port to the printhead, and a third fluid path connecting the third fluid port to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.",SILVERBROOK RES PTY LTD;;JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/092-473-202-619-977,Patent Application,yes,2,7,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/18;;B41J2/19,,1,0,,,See also references of EP 2571697A4,PENDING
148,EP,A2,EP 3132941 A2,095-460-472-839-44X,2017-02-22,2017,EP 16189612 A,2011-05-16,US 34557210 P;;EP 11782764 A;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,"A system for distributing fluid and gas within a printer is provided having a fluid container (310) having three fluid ports (311), a first fluid path (380) connecting the first fluid port (313) to a printhead (200) of the printer, a second fluid path (382) connecting the second fluid port (315) to the printhead, and a third fluid path (333) connecting the third fluid port (317) to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.
",MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/095-460-472-839-44X,Patent Application,yes,1,1,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/165;;B41J2/175;;B41J2/18,,0,0,,,,ACTIVE
149,EP,A4,EP 2571697 A4,037-040-575-650-442,2015-01-07,2015,EP 11782764 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,,MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,ZAMTEC LIMITED (2014-02-12);;MEMJET TECHNOLOGY LIMITED (2014-09-24);;MEMJET TECHNOLOLGY LIMITED (2014-08-13),https://lens.org/037-040-575-650-442,Search Report,no,6,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/165;;B41J2/175;;B41J2/18,,1,0,,,See also references of WO 2011143698A1,ACTIVE
150,EP,B1,EP 2571697 B1,101-314-811-184-231,2016-11-16,2016,EP 11782764 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,SYSTEM FOR DISTRIBUTING FLUID AND GAS WITHIN PRINTER,,MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,ZAMTEC LIMITED (2014-02-12);;MEMJET TECHNOLOGY LIMITED (2014-09-24);;MEMJET TECHNOLOLGY LIMITED (2014-08-13),https://lens.org/101-314-811-184-231,Granted Patent,yes,8,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/165;;B41J2/175;;B41J2/18,,0,0,,,,ACTIVE
151,AU,A1,AU 2011/256127 A1,151-613-075-082-328,2012-11-29,2012,AU 2011/256127 A,2011-05-16,US 34557210 P;;AU 2011/000572 W,2010-05-17,System for distributing fluid and gas within printer,"A system for distributing fluid and gas within a printer is provided having a fluid container having three fluid ports, a first fluid path connecting the first fluid port to a printhead of the printer, a second fluid path connecting the second fluid port to the printhead, and a third fluid path connecting the third fluid port to a gas vent. The first and second fluid ports are configured so that fluid from the fluid container flows between the first and second fluid paths via the printhead and the third fluid port is configured so that gas flows between the fluid container and gas vent.",ZAMTEC LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/151-613-075-082-328,Patent Application,no,0,0,60,60,0,B41J2/18;;B41J2/19;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/1752;;B41J2/17553;;B41J2/17556;;B41J2/19;;B41J2202/02;;B41J2/16535;;B41J2/16541;;B41J2/16585;;B41J2/175;;B41J2/17556;;B41J2/19;;B41J2/1752;;B41J2/17553,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
152,AU,B2,AU 2013/216640 B2,156-007-965-161-302,2014-11-20,2014,AU 2013/216640 A,2013-08-15,AU 2011/256127 A;;AU 2013/216640 A,2011-05-16,SYSTEM FOR REDUCING INK COLOR MIXING EFFECTS IN PRINTER,"Abstract A system for reducing ink color mixing effects in a printer. The system includes: a printhead having multiple ink color channels, the printhead being mounted within the printer at a first level; and a plurality of ink containers mounted within the printer so as to be fluidically connected to the printhead, the plurality of ink containers being positioned in an array having a plurality of levels which are lower than the first level. The plurality of ink containers includes: a black ink container which supplies black colored ink to a black ink color channel of the printhead, the black ink container being disposed at the lowest level defined by the array; and a yellow ink container which supplies yellow colored ink to a yellow ink color channel of the printhead, the yellow ink container being disposed at the highest level defined by the array.",MEMJET TECHNOLOGY LTD,JOHNSON ERIC;;GAO JINSONG;;BOUND ANDY;;ROETKER THOMAS;;OLSON JON;;LUCAS JON;;ROOT RYAN;;FISHBEIN PAUL;;SEITER PAUL;;WILLIAMS GREG;;BAILEY JOHN;;YRACEBURU BOB;;WEISKOPF PAUL;;ESCOBEDO VICTOR;;KELLEY RICHARD ALAN;;LOVE JOHN CHRISTIAN;;LUESCHEN JEFFREY D;;JOHNSON JEFFREY;;HIBBARD CHRISTOPHER;;KWAN KENT BENJAMEN;;DYER GEOFFREY PHILIP;;ESDAILE-WATTS EDWARD ELLIS,,https://lens.org/156-007-965-161-302,Granted Patent,no,2,0,2,2,0,,B41J2/19;;B41J2/18,,0,0,,,,ACTIVE
